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Summary 
Photodynamic therapy (PDT) is clinically-approved in the treatment of angiogenic disorders, 
particularly eye diseases such as age-related macular degeneration (AMD) and skin cancers, 
such as basal cell carcinoma. PDT causes vascular occlusion resulting in hypoxia and 
inflammation, which induces the activation of the hypoxia inducible factors and the release of 
vascular endothelial growth factor, amongst other pro-angiogenic factors. This leads to the 
activation angiogenic pathways and the biological response of revascularization of treated 
areas. Therefore, the use of PDT in combination with anti-angiogenic strategies could increase 
treatment efficiency for diseases such as AMD by extending the photodynamic angio-occlusive 
effects. 
The aim of this research is to compare the effectiveness of Visudyne®-PDT in combination with 
one of two drugs targeting angiogenesis through different mechanisms: 1) direct targeting of 
VEGF, the clinically targeted pathway in AMD, by means of the antibody Avastin®, and 2) 
blocking the angiogenic signaling pathway with a receptor tyrosine kinase inhibitor, Sutent®. 
These compounds were tested on the chicken chorioallantoic membrane (CAM) with and 
without PDT. When drugs were topically applied during early stages of embryonic development 
to inhibit physiological angiogenesis, fifty percent inhibition (ED50) is seen at 45 and 200 μM for 
Avastin® and Sutent®, respectively. To study the effects of drug inhibition on an induced 
angiogenic state, closure of small blood vessels is achieved through Visudyne®-PDT. Vascular 
regrowth following photodamage is significantly inhibited by both drugs, with an ED50 of 7 and 17 
μM for Avastin® and Sutent®, respectively. These results suggest the therapeutic potential of the 
tyrosine kinase inhibitor for application in combination with PDT strategies. The use of small 
molecule drugs could lead to more optimal application of anti-angiogenic compounds via 
droplets or slow-release drug delivery systems. 
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Introduction 
Angiogenesis 
Angiogenesis is defined as the formation of new blood vessels from pre-existing capillaries (1). 
This term was coined in 1935 in order to describe the formation of new blood vessels in 
placenta (2). The survival of all cells and tissues is dependent on angiogenesis, due to the 
transportation of gasses and nutrients in the blood through the vascular network. Angiogenesis 
is therefore incredibly important to many normal physiological processes such as normal tissue 
growth, embryonic development, wound healing and menstruation (1). In the same sense, the 
inability of the body to properly control angiogenesis can lead to many severe disease states. 
Inadequate angiogenesis can lead to ischemic tissues (tissues with restricted blood flow) and 
cardiac failure, while abnormally high levels of angiogenesis can result in pathological 
processes such as: cancer, age-related macular degeneration (AMD), cardiovascular diseases 
(atherosclerosis), chronic inflammation (rheumatoid arthritis, Crohn‟s disease), diabetes 
(diabetic retinopathy), psoriasis, endometriosis and adiposity (3; 4).  
Blood vessels are lined by endothelial cells which are in direct contact with blood. Below the 
monolayer of endothelial cells, blood vessels are surrounded by pericytes (structural support 
cells), smooth muscle cells, fibroblasts, the basement membrane (BM) and the extracellular 
membrane (ECM) (1). Endothelial cells are metabolically active and selectively permeable to 
small solutes and peptides/proteins. They also play a key role in many regulatory processes in 
the body including: regulation of blood coagulation (5); directing cells of the immune system to 
specific sites in the body through the release of chemo-attractants, cytokines and chemokines 
(6); aiding in vascular remodeling and being directly involved in the angiogenic cascade (1).  
The process of angiogenesis is characterized by the formation of new vessels from preexisting 
vessels, capillaries and postcapillary venules (7). Angiogenesis is initiated by the release of pro-
angiogenic factors which activate signaling cascades. The increased release of pro-angiogenic 
factors is normally in response to the release of cytokines by cells in a hypoxic (low oxygen) or 
ischemic environment (1). The transition from quiescent or non-proliferative vasculature to 
angiogenic vasculature is marked by a change in the balance between pro- and anti-angiogenic 
factors.  
Endothelial cell activity is always the first process to initiate angiogenesis in all situations. It is 
believed that vascular endothelial growth factor (VEGF) is the most important molecule involved 
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in the initiation of angiogenesis (1). This hypothesis is supported by the fact that the release of 
VEGF results in vasodilation through endothelial cell production of nitrous oxide, which 
increases endothelial cell permeability, a pre-requisite for endothelial cells to enter the 
angiogenic cascade (1; 8). Increased endothelial cell permeability allows plasma proteins to 
enter the tissue and form a fibrin-rich provisional network to support the growth of new blood 
vessels (9). VEGF‟s importance in initiating the angiogenic cascade is supported by the fact that 
its production is controlled by hypoxia inducible factors (HIF) and the fact that the VEGF 
receptor (VEGFR) is over expressed in hypoxic or ischemic conditions (10). Even though VEGF 
is arguably the most important factor involved in angiogenesis, evidence has shown that 
angiogenesis in not entirely VEGF dependent (11). 
In the process of angiogenesis, activated endothelial cells migrate to the desired location of the 
body, degrading the BM of the parent venule in order to move towards an angiogenic stimulus. 
The endothelial cells elongate and align to create a solid sprout, while the lumen of the vessel is 
formed by a curvature in each endothelial cell (12). The endothelial cells continue to proliferate, 
increasing the length of the sprout, until finally two hollow sprouts will join at their tips to create a 
loop and allow blood to flow. Pericytes then line the base of the loop and new sprouts can grow 
from its apex (13). 
The exact process of these last steps of angiogenesis is not entirely understood, but the 
process is believed to be guided by specialized cells at the front of the sprout called „tip cells‟. A 
study conducted by Gerhardt et al. on angiogenesis in the retina of mice found that retinal 
vessels grow in expanding circles (14). These sprouts were guided by specialized tip cells 
supported by highly proliferative stalk cells. This study revealed that the tip cells are highly 
polarized and uniquely responsive the VEGF-A isoform. Tip cells grow by extending along 
filopodia which follow astrocyte cell tracks. The filopodia can guide the tip cells by detecting 
VEGF-A gradients, which are created by astrocytes. The stalk cells are also specifically 
responsive to VEGF-A, but to its absolute concentration and not its gradient (14). 
Adult vasculature is mainly quiescent with the exception of organs which undergo ongoing 
angiogenesis, such as the female reproductive organs, organs that undergo physiological 
growth, or injured tissues (15).  
Angiogenic factors 
Physiologic angiogenesis is a very complicated process which involves many different pro- and 
anti-angiogenic stimuli including many growth factors and environmental factors. Vascular 
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endothelial growth factor (VEGF) is the most potent and best understood of these growth factors 
(1). It belongs to the VEGF-PDGF supergene family, which contains 5 isoforms based on 
alternative exon splicing (VEGF-A, VEGF-B, VEGF-C, VEGF-D and VEGF-E). Out of these 
factors, VEGF-A is the most potent growth factor and is frequently referred to as simply VEGF 
(16). VEGF is responsible for the regulation of angiogenesis through the following mechanisms: 
increasing micro-vascular permeability to plasma proteins (17); inducing endothelial cell division 
and migration (18; 19); promoting endothelial cell survival through interactions with ECM 
components, such as αvβ3 integrin, which prevents apoptosis (20) and reverses endothelial cell 
senescence (21; 22); promoting stromal degradation and possibly increasing the formation of 
extravascular fibrin substrate for endothelial and tumor cell growth (23; 24). VEGF is also 
believed to induce the expression of proteases and receptors involved in cellular invasion and 
tissue remodeling (25; 26). Loss of VEGF signaling can result in apoptosis of endothelial cells 
(15). This family of ligands interacts with three receptor tyrosine kinases: VEGFR-1/FLT-1, 
VEGFR-2/FLK-1/KDR and VEGFR-3/FLT-4; however its angiogenic effects are mainly due to 
binding with VEGFR-1 and -2 found predominantly on vascular endothelial cells (24; 27). 
VEGFRs, however, are not only expressed on the vascular endothelium, but also on 
monocytes, macrophages and some tumors cells (1). VEGF is mainly produced by angiogenic 
endothelial cells, but can also be produced in hypoxic tumor cells, macrophages and other 
immune cells (28). VEGF-A binds with greater affinity to VEGFR-1 than VEGFR-2, but it is 
believed that VEGFR-1 mainly acts as an intermediate receptor, controlling the availability of 
VEGF-A to VEGFR-2, which is mainly responsible for VEGF-related signaling (24; 29). 
Other important pro-angiogenic factors include the basic fibroblast growth factor family, (bFGF 
also referred to as FGF2) and the platelet-derived growth factor (PDGF) (16). There are also 
many ECM components which can have effects on angiogenesis and endothelial cell 
morphology including: integrins, throbospondin, laminin and osteonectin. Integrin αvβ3 plays a 
particularly critical role in angiogenesis due to the fact that its inhibition results in endothelial cell 
apoptosis and the fact that it mediates cellular adhesion to many factors (30). In addition, it is 
minimally expressed in quiescent endothelial cells while being up-regulated in angiogenic 
endothelial cells (31).  
In addition to the molecules and pathways mentioned above, there are also other cell types and 
environmental factor which can affect angiogenesis including: immune cells, periendothelial 
cells and environmental factors such as hypoxia (1). Hypoxic conditions are capable of inducing 
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angiogenesis through the activation of HIF, which in turn causes the release of VEGF and other 
pro-angiogenic factors (1). 
The decision for a blood vessel to remain quiescent or become angiogenic is dependent on 
many different signals of varying importance, some of which are briefly discussed above. 
Interactions with these pathways can be achieved through many different mechanisms and can 
provide the ability to control angiogenesis for therapeutic purposes. 
Receptor tyrosine kinases  
Many important angiogenic factors such as VEGFs, PDGF, FGFs, and epidermal growth factor 
(EGF) interact with endothelial cells through receptors which are transmembrane cell signaling 
proteins called receptor tyrosine kinases (RTKs) (32; 16). RTKs are responsible for transducing 
extracellular signals to the interior of cells and are involved in many different pathways in the 
body, including cell proliferation and migration (16). An overview of different pathways involved 
in angiogenesis which are activated by RTKs can be seen in Figure 1 (adapted from Gotink et 
al. (16)). The most common RTK involved in angiogenesis is the VEGFR (16).  
 
Figure 1 Overview of receptor tyrosine kinase signaling pathways involved in 
angiogenesis (16). 
 
7 
 
 
A typical RTK monomer is shown in Figure 2 (16). A monomer consists of an N-terminal 
extracellular ligand-binding domain, a transmembrane domain and a C-terminal intracellular 
domain with tyrosine kinase activity. The kinase domain has two lobes, with an ATP-binding 
cleft located between the N- and C-terminal lobes (16). An angiogenic factor can act as a ligand 
to a RTK by binding to its extracellular domain, inducing dimerization of the receptor and 
autophosphorylation of the kinase domain located on the interior of the cell (33). The RTK is 
then capable of transferring a phosphate group from a high-energy donor molecule, such as 
ATP, to a specific substrate (33). ATP normally binds to a kinase receptor by forming an H-bond 
from its adenine ring to the ATP-binding cleft of the kinase. The transfer of a phosphate group 
from the ATP molecule to the substrate results in the phosphorylation of the substrate, which 
induces a functional change (16). The substrate is then capable of transducing the signal 
through the activation of a specific signaling pathway. Simultaneous activation of many signaling 
pathways results in a biological response (34). 
 
Due to their pivotal role in the activation of angiogenic signaling pathways, RTKs can be 
targeted as a means to control angiogenesis for therapeutic reasons. This can be achieved 
through the use of receptor tyrosine kinase inhibitors (RTKIs), which are small-molecules that 
 
Figure 2 The structure of a receptor tyrosine kinase, showing the ATP binding site which the receptor tyrosine kinase 
inhibitor competitively binds to (16). 
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competitively interfere with the ATP binding site (shown in Figure 2) (16). There exist three 
categories of RTKIs. Type I kinase inhibitors, which include Sutent®, recognize the active 
conformation of the kinase and bind to the ATP-binding site by presenting one to three H-Bonds 
which mimic bonds normally formed by ATP. Due to the fact that the ATP binding site is mostly 
conserved in all RTKs, type I inhibitors always occupy the adenine region of ATP-binding site, 
and it is therefore hard to have a type I inhibitor which is highly selective (16). Type II kinase 
inhibitors recognize the inactive confirmation of the kinase and indirectly compete with ATP by 
occupying the hydrophobic pocket right next to ATP-binding site. Finally, type III kinase 
inhibitors, which are known as „covalent‟ inhibitors, covalently bind to the cysteines at a specific 
site in the kinase, blocking the binding of ATP (16). 
Exudative age-related macular degeneration 
Overview 
Age-related macular degeneration (AMD) is a retinal disease, which represents the leading 
cause of vision loss and legal blindness in the elderly populations of developed countries (35). 
AMD is characterized by abnormalities in four structure of the macular region: the 
photoreceptors, the retinal pigment epithelium (RPE), the Bruch‟s membrane and the 
choriocapillaries (36). An overview of these structures and their abnormalities in patients 
suffering from AMD is shown in Figure 3 (37). There are two variations of AMD: the atrophic 
form of AMD and the angiogenic or exudative form of AMD. Exudative AMD is the faster- 
progressing form of AMD, and is characterized by the growth of abnormally leaky blood vessels 
in the choroid layer of the eye, called choroidal neovessels (CNVs) (36). The choroid is a 
vascular layer located between the retina and sclera (38). In AMD, these CNVs cause the 
leakage of blood and fluids in the macular region of the eye responsible for the central field of 
vision, resulting in vision impairment (36). The exact cause of the growth of these CNVs is 
unknown, but is believed to be related to a lack of oxygen and other nutrients in the 
photoreceptors (39; 40). A typical example of the type of vision loss suffered by patients with 
AMD is shown in Figure 4 (41). The exudative form of AMD is the focus of this study and will be 
referred to as only AMD hereafter. 
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Treatment options for AMD 
Current forms of treatment for AMD, which can help to manage symptoms and slow disease 
progression, include: laser treatment (thermal laser photocoagulation and transpupillary 
thermotherapy) (42), PDT (43), and anti-angiogenic drug therapy (43). Laser treatment uses 
laser light in order to non-specifically photo-coagulate CNVs, sealing off leaky blood vessels. 
This form of treatment, however, results in many small retinal scars causing blinds spots in the 
patients‟ field of vision and, therefore, is no longer widely used (42). Both photodynamic and 
anti-VEGF therapies have been shown to be safe and effective treatments for AMD which 
specifically target abnormal blood vessels. The specific inhibition of diseased CNVs with PDT or 
anti-angiogenic drug therapy presents the advantage of resulting in minimal damage to retinal 
vessels, normal choriocapillaries, retinal pigment epithelium and nearby photoreceptors (43; 
44). These therapies result in some degree of closure of malignant blood vessels, allowing 
normal choriocapillaries to regrow in their place resulting in improved visual acuity (45; 46).  
Clinically-approved treatments for AMD include the use of Visudyne®-PDT and two anti-
angiogenic drugs: Lucentis® (ranibizumab, Novartis) and Macugen® (pegaptanib sodium, 
EyeTech) (47; 48; 39). Both of these drugs target the pro-angiogenic growth factor VEGF to 
inhibit blood vessel growth (42). The anti-angiogenic drug Lucentis® is a humanized monoclonal 
antibody targeting VEGF, while Macugen® is an aptamer or pegylated modified RNA 
 
Figure 4 An example of vision loss as a result of AMD 
(41). 
 
 
Figure 3 An overview of the structure in the eye affected 
by AMD. The top image shows a normal eye, while the 
bottom image shows the effects of AMD (37). 
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oligonucleotide with a high affinity for VEGF (36). In addition to these drugs which have already 
been approved, there are additional anti-angiogenic drugs which are still under investigation, 
including: anecortave acetate (a steroid) (49); triamcinolone acetonide (50); squalamine lactate 
(a steroid compound) (51); Sirna-027 (a small interfering RNA) (52); VEGF-Trap (a decoy 
receptor) (53) and angiostatin, endostatin and PEDF (anti-angiogenic factor) (54; 36).  
In the literature there are some studies examining the effect of small molecule-based RTKIs on 
eye disease. For example, the application of the RTKI CGP 41251 to CNVs growing in mice due 
to retinal damage caused by photocoagulation resulted in a dramatic decrease in the growth of 
CNVs in treated mice when compared to control mice, suggesting some support for the use of 
an orally bioavailable RTKI in the treatment of AMD (55). 
The use of slow-release drug delivery systems has also been investigated for the treatment of 
vitreoretinal diseases, such as AMD (56). These devices can help to overcome some of the 
complications normally associated with drug delivery to the eyes. Complications include 
problems with delivery of systemically administered drugs to the retina, due to its unique 
situation of being separated from systemic circulation by the inner and outer blood retinal 
barriers (56). The application of drugs through eye drops is also not ideal, due to difficulties 
achieving therapeutically-relevant concentrations because of low absorption and washing away 
of drugs as a result of tear production (57). Due to these complications, most drugs must be 
administered directly into the eye through intravitreal injections. This, however, is also not 
without complications such as vitreous hemorrhage, endophthalmitis and retinal detachment 
(56). In addition, many low molecular weight drugs have short half-lives (as short as a few 
hours) in the vitreous cavity, requiring multiple drug applications in order to maintain therapeutic 
drug concentrations (58). All of these complications and limitations have resulted in a need for 
the development of slow-release drug delivery systems for the treatment of eye diseases such 
as AMD. Some of the devices which are under investigation and their potential for improving 
treatment of AMD are discussed in the paper by Yasukawa et al (56).  
More recently, the use of implantable telescopes has also been approved for the treatment of 
AMD. These microscopes magnify images, thereby reducing the relative size of the blind spot in 
the center of the field of vision caused by the macular degeneration. This treatment, however, is 
only used in extreme cases for patients with severe vision loss, reaching the end stage of 
advanced macular degeneration (42). 
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Avastin® vs. Lucentis® 
Avastin®, one of the drugs under investigation in this study, is not clinically-approved for the 
treatment of AMD, but is frequently used „off-label‟ for this indication. Avastin® is clinically-
approved for the systemic treatment of certain forms of cancer such as colon cancer (59), and is 
currently under consideration for the treatment of AMD. Lucentis®, one of the anti-angiogenic 
drugs clinically-approved for the treatment of AMD mentioned above, is derived from the same 
anti-VEGF mouse monoclonal antibody as Avastin® (60). While Avastin® is comprised of the full 
length antibody; Lucentis® consists of only the antigen-binding fragment, making it a much 
smaller molecule (60). An overview of the modifications made to the antibody in order to 
generate these drugs can be seen in Figure 5 (61). Lucentis® was specifically developed and 
approved for the treatment of eye disease (60). Even though both molecules bind to VEGF at 
the same position, they vary in size, affinity, speed of clearance from the eye and cost (62). 
Both drugs are administered through intravitreal injection either on a monthly or an as-needed 
regiment. The widespread „off-label‟ use of Avastin® for the treatment of AMD has developed as 
a result of the similarities between these drugs, the vast price difference between them 
(approximately $50 per dose of Avastin® compared to $2,000 per dose of Lucentis®), and an 
overall lack of evidence showing that Lucentis® is more effective than Avastin® (60). 
 
Figure 5 An image of the mouse antibody which is used to generate Avastin® and 
Lucentis® and the modification made to the antibody to generate each of the drugs (61). 
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In order to determine the efficacy of these two drugs, a large, prospective, multicenter 
randomized clinical trial was performed called the Comparison of AMD Treatment Trials (CATT) 
(63). In this study, optical coherence topographies (OCT) were used in order to monitor disease 
progression following treatment and identify fluid leakage from blood vessels. First-year results 
from this study showed that monthly use of Avastin® and Lucentis® resulted in the same visual 
acuity outcome. OCT results showed better retinal thickness measurements for Lucentis®-
treated patients, which may be reflected in the visual acuity measurements for the second year 
check point, but were not evident at the end of the first year. This study also showed equivalent 
visual acuity outcomes for the monthly and as-needed treatment regime for Lucentis®. As-
needed treatment for Avastin® and Lucentis® appeared similar, but the as-needed treatment 
regime for Avastin® was not as effective as the monthly regiment for either drug. This may be 
due to Avastin® therapy resulting in shorter treatment benefits for a subgroup of patients 
requiring more frequent drug administration (60; 63). Overall, these results are very positive for 
patients, as it supports the use of Avastin®, a much less expensive drug than Lucentis®, and 
suggests that monthly treatments may not always be necessary.  
Visudyne®-PDT 
Visudyne®-PDT is commonly used for the treatment of AMD with relatively good results (36; 64). 
Studies have shown that Visudyne® preferentially accumulates in the neovasculature (including 
CNVs); however animal models have shown that some drug is also present in the retina (65). 
Visudyne®-PDT may, therefore, result in some damage to retinal pigmented epithelium and 
outer nuclear layers of the retina. Temporary occlusion of CNVs following Visudyne®-PDT in 
humans has been confirmed by fluorescein angiography (65). 
Two double-masked, placebo-controlled, randomized studies on patients suffering from classic-
containing subfoveal CNVs secondary to age-related macular degeneration were conducted in 
order to ascertain the effectiveness of Visudyne®-PDT (66; 65). A total of 609 patients (402 
Visudyne® and 207 placebo) were involved in the two studies. Patients were treated and the 
vascular effects of the treatment were monitored using fluorescein angiograms. If blood vessel 
leakage was not entirely arrested or if a leakage returned, as detected by angiograms, 
retreatment was allowed every 3 months. The results of these studies showed that a statistically 
significant difference could be seen between patients treated with Visudyne®-PDT and control 
patients at both the 1 and 2 year check for visual acuity measurements. A subgroup of patients 
with classic CNV lesions (n=242, Visudyne®=159, placebo=83), defined as those where classic 
components comprised 50% or more of the whole lesion area, showed a difference of 
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approximately 28% between groups at 12 and 24 months for the primary efficacy endpoint 
(defined as the percentage of patients who lost <3 lines of visual acuity). In this subgroup, 
severe vision loss ( 6 lines of visual acuity from baseline) occurred in 12% of Visudyne®-treated 
patients compared to 36% of placebo-treated patients. Patients with predominantly classic CNV 
lesions without occult CNVs showed the greatest treatment benefit, with a 49% difference 
between treatment groups at the 1 year check point (assessed by <3 lines-lost definition). Older 
patients ( 75), patients with dark irises, occult lesions or less that 50% classic CNVs are less 
likely to benefit from PDT (66; 65). 
These treatment modalities for AMD have been shown to be relatively effective; however, their 
beneficial results are only transient and no long term-cure is yet available. This is due to the fact 
that leaky blood vessels are only temporarily stabilized and the formation of new blood vessels 
which can become diseased in not prevented. In addition, PDT actually promotes the regrowth 
of new blood vessels by creating a hypoxic environment through vascular occlusion. Hypoxia 
results in the release of pro-angiogenic factors and initiation of angiogenic signaling pathways 
(43). This process accelerates the regrowth of malignant vasculature and therefore the 
recurrence of disease symptoms. The recurrence of vision loss necessitates re-treatment and is 
the major motivation for the adaptation of combination therapies, which could prevent or slow 
the regrowth of blood vessels following treatment. 
Cancer 
Although exudative AMD is the primary focus of treatment for the research conducted in this 
study, many of the implications of these results can be carried over to cancer research. This is 
primarily due to the fact that like AMD, tumor growth is accompanied by abnormally angiogenic 
vasculature, and the fact that therapeutic benefit can be seen for cancer patient‟s treatment with 
anti-angiogenic drugs and PDT. In addition, the use of a combination of anti-angiogenic and 
photodynamic therapies present many potential benefits in the treatment of certain forms of 
cancer.  
In 1971, Judah Folkman first proposed the theory that tumor growth is angiogenesis-dependent, 
and that targeting the neovascularization of tumors could provide a new form of cancer therapy 
(67). This theory was supported by a study performed in 1963, which showed that tumors 
implanted in isolated perfused organs failed to grow larger than a few millimeters, but when the 
same tumors were reimplanted into donor mice they grew rapidly killing the host (68). It was 
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believed that the perfused organ created an environment where neovascularization was 
inhibited, limiting the tumor‟s growth (13). 
This was followed by a study in 1968, which showed that tumors could induce new capillary 
vessel growth even if they are separated from the vascular bed of the host by a Millipore filter 
(69). This lead to the hypothesis that tumors are capable of releasing a diffusible angiogenic 
factor or are capable of degrading an inhibitory factor, giving them the capability to initiating 
angiogenesis (13). 
It is now widely accepted that tumors are angiogenesis-dependent and their ability to have 
sustained angiogenesis has been included as one of the hallmarks needed for the development 
and progression of cancer (70).  
Cells initially lack the ability to induce angiogenesis, which limits their ability to grow. It is 
therefore believed that tumors must develop this ability, through what is referred to as an 
„angiogenic switch‟, where the balance between angiogenesis inducers and inhibitors is 
switched to favor angiogenesis (70). The „angiogenic switch‟ is believed to be the rate-limiting 
secondary step to developing multi-stage carcinoma (71). 
The „angiogenic switch‟ is normally accompanied by the increased expression of VEGFs and/or 
FGFs, or the down-regulated expression of angiogenesis inhibitors, such as thrombospondin-1 
or β-interferon or both. Pro-angiogenic factors secreted by tumor cells stimulate proliferation and 
migration of endothelial cells, resulting in the outgrowth of new capillaries into the tumor (70). 
Each tumor type utilizes different molecular strategies to initiate the „angiogenic switch‟ (70). 
The theory that cancer is angiogenesis-dependent, and that the angiogenic phenotype is 
dependent on the expression of pro-angiogenic factors, is supported by the fact that serum 
concentrations of VEGF are 6.5 times higher in colon carcinoma patients when compared to 
healthy individuals, and that high serum levels of VEGF is strongly associated with reduced 
overall survival and disease-free survival (72; 73; 74).  
The link between cancer and angiogenesis is further strengthened by evidence which shows 
that many cancer-related genetic changes thought to result from mutations in tumor suppressor 
genes and oncogenes also result in angiogenic endothelial cells. Many oncogenes, such as c-
myb, sis and src, cause increased expression of molecules that induce angiogenesis. For 
example, the mutated ras gene strongly upregulates TGF- α, TGF-β, and VEGF, and can also 
indirectly affect angiogenesis through the production and activation of the BM and ECM-
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degradation enzymes (1). Another example is the mutation of the VHL gene, which is normally 
involved in the degradation of HIF-1α. The mutated VHL gene is no longer capable of breaking 
down HIF-1α, which can result in upregulation of VEGF, EGFR, and PDGF, and the induction of 
angiogenesis (70; 75). 
The „angiogenic switch‟ is very dependent on the expression of VEGF, due to the fact that it is 
the most potent pro-angiogenic factor. The most common way to inhibit angiogenesis is, 
therefore, through drugs which target VEGF or its receptors (16).  
Tumor angiogenesis 
The „angiogenic switch‟ is viewed as a discrete phase of tumor growth, which can occur at any 
stage of tumor development depending on the tumor and its microenvironment (15). Tumor 
angiogenesis is thought to go through two distinct phases. The first stage is the avascular 
phase, characterized by a small, occult lesion with a diameter less than 1-2 mm; this type of 
lesion will stay dormant by reaching a steady state between proliferation and apoptosis (15). A 
small percentage of these tumors will leave the dormant stage to enter the second phase of 
tumor angiogenesis, considered the vascular phase, which is characterized by exponential 
growth (15). 
 
 
Figure 6 Overview of the interaction between a blood vessel and tumor cells, which results in the 
growth of new blood vessels towards the tumor (76). 
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There are many different pathways by which a tumor can induce angiogenesis, some of which 
are described below (13). Tumors can release their own angiogenic factors; each tumor type will 
release a combination of different factors in order to initiate angiogenesis. Macrophages can be 
attracted and activated to release angiogenic factors. Collagenases and heparanasese, which 
store angiogenic factors in the ECM, can be secreted and vascular permeability factors can be 
released, which cause leakage of fibrinogen from postcapillary venules to stimulate 
angiogenesis. An example of the type of interaction between tumor cells and nearby vasculature 
which can result in angiogenesis is shown in Figure 6 (76). This figure shows the tumor cells 
releasing pro-angiogenic factors (in this case VEGF) which activate nearby endothelial cells, 
resulting in angiogenesis toward the tumor. 
Tumor vasculature is significantly different from normal vasculature due changes in the balance 
between pro- and anti-angiogenic factors (15). Some distinct characteristics of tumor 
vasculature include: aberrant vascular structures, i.e. vessels are irregularly shaped, dilated and 
tortuous, even having dead ends; altered endothelial-cell pericyte interactions characterized by 
loosely-associated pericytes and less dense pericyte coverage (77); abnormal blood flow which 
is slowed and sometimes oscillating, resulting in dysfunctional capillaries; increased vessel 
permeability causing leaky and hemorrhagic vessels due to over expression of VEGF and 
vessel characterized by delayed maturation (77; 15). These differences are due to the non-
physiologic balance of pro- and anti-angiogenic factors and to the reduced association of 
pericytes with blood vessels. Reduced pericyte coverage allows for increased proliferation of 
endothelial cells resulting in vessels with abnormal structure, such as the increased thickness or 
tortuosity mentioned above, and results in vasculature which has increased sensitivity to the 
inhibition of VEGF signaling (15).  
It has been hypothesized the unorganized nature of tumor vasculature may be due to 
misguiding of the filopodia which guide tip cells. One study showed that tumor vessels had 
misguided filopodia similar to those of transgenic mice overexpressing VEGF (14). Tumor 
hypoxia can also complicate the angiogenic activity of cancer cells and can result in tumor 
vasculature which is never quiescent and constantly growing. It should also be noted that 
research has shown that angiogenic activity does not necessarily correlate with the 
aggressiveness of a tumor (15). 
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Anti-angiogenic drug therapy 
General information, advantages and disadvantages 
Based on his theory regarding the dependence of tumor growth on angiogenesis, Judah 
Folkman proposed targeting the neovascularization of tumors as a new form of cancer therapy 
(67; 16). Now that cancer‟s dependence on angiogenesis has been widely accepted, targeting 
tumor angiogenesis has become a viable form of cancer therapy. 
As previously described, angiogenesis is dependent on many pro- and anti- angiogenic 
signaling pathways. This study focuses on the use of two particular anti-angiogenic agents: the 
monoclonal antibody Avastin®, which directly target VEGF, and a RTKI, Sutent®, which inhibits 
VEGFR, thus preventing angiogenic signal transduction. An overview of many of the different 
pathways that can be targeted by anti-angiogenic drugs is shown in Figure 7 (78). The particular 
pathways of Sutent® and Avastin® are outlined in red and blue, respectively.  
 
Figure 7 Overview of potential targets of anti-angiogenic drugs in cancer treatment. Sutent® (sorafenib) (outlined in red 
in the figure) is shown targeting receptor tyrosine kinases in the tumors endothelium, while Avastin® (bevacizumab) 
(outlined in blue) is shown directly targeting VEGF molecules (78). 
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Due to the fact that there are many angiogenic signaling pathways and many pro-angiogenic 
factors in the body, there exist many pathways by which angiogenesis can be targeted; but, 
there exist equally as many by which a tumor can evade this form of therapy, compensating for 
an inhibited factor through the increased expression of other factors (23). These mechanisms 
form the basis for one of the main complications associated with anti-angiogenic drug therapy: 
drug resistance. This also makes the combination of multiple anti-angiogenic drugs therapies an 
attractive therapeutic option, which could provide increased benefits (23). Even though the 
development of drug resistance has complicated the use of anti-angiogenic drug therapies in 
clinical applications, beneficial results are frequently seen with this form of therapy, as well as 
synergistic effects when they are used in combination with either chemo- or radiation therapy 
(23). 
 
Figure 8 Table of selected anti-angiogenic receptor tyrosine kinase inhibitors, their target RTKs, clinical application and 
stage of development (79). 
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The use of anti-angiogenic agents for the treatment of angiogenesis based disorders has shown 
a lot of therapeutic potential and is a field that is strongly researched. Many anti-angiogenic 
drugs are currently under development, involved in clinical trials or are being used in the 
treatment of angiogenesis disorders, particularly cancer. A table of selected RTKIs in different 
stages of development can be found in Figure 8 (79). Some of the general advantages and 
disadvantages of anti-angiogenic drug therapy will be discussed before each of the two drugs 
being specifically investigated in this study are described in more detail.  
Anti-angiogenic drug therapy has been shown to be a relatively reliable and safe form of 
treatment for patients suffering from AMD and remains one of the best therapeutic options for 
this disease. More interestingly, however, is the use of anti-angiogenic drug therapy for the 
treatment of cancer, as it presents some unique advantages over other common forms of 
cancer drug therapy. Drug resistance is one of the major factors which contribute to the failure 
of certain types of cancer treatments, such as chemotherapy. It is believed to be caused by one 
of two mechanisms: through mutations in growth factor receptor signaling genes, or, as in the 
case of classic multi-drug resistance, the reduced energy-dependent uptake of anti-cancer 
drugs by drug efflux transporters due to the cloning of multidrug transporters such as P-
glycoprotein (Pgp) (80; 81). It is believed that the development of drug resistance to anti-
angiogenic drugs through these sorts of mutations may be avoidable as they target the tumor 
endothelium instead of the tumor cells themselves. Tumors must recruit these endothelial cells 
in order to create the vasculature they need to survive and grow. These endothelial cells are 
genetically more stable than the tumor cells, meaning that they are less susceptible to 
developing mutations that could lead to drug resistance (23). In addition, some RTKIs may be 
substrates and/or modulators of these multi-drug transporters, such as Pgp, and therefore may 
be able to bypass this mechanism of resistance (80; 81). This advantage, however, is 
considered controversial as much evidence has supported the ability of cancer to develop 
resistance to anti-angiogenic drugs, as well as results from clinical trials showing the 
development of drug resistance. 
Although anti-angiogenic drug therapy is an effective form of treatment for AMD and some 
forms of cancer, it is still subject to limitations and has certain side effects and toxicities. 
Significant clinical toxicities to anti-angiogenic drug therapies have been observed and include: 
gastro-intestinal perforation, hypertension and reduced left ventricle ejection fraction (LVEF), 
thyroid disturbances and fatigue, kidney damage, sever bleeding, skin toxicities, and disturbed 
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wound healing (16; 82). An overview of anti-angiogenic drug therapy-related side effects and 
some of their underlying causes can be seen in Figure 9 (82).  
 
Another possible drawback of anti-angiogenic drug therapy for cancer treatment is the 
suggestion by multiple sources that this form of therapy can result in “malignant progression of 
tumors to increased local invasion and distant metastasis” (83) or “accelerated metastasis” (84; 
23). As with the development of resistance to this form of therapy, the relationship between anti-
angiogenic drugs and metastasis is not well understood and is still a central point of debate. 
Paez-Ribes et al. (83) reported that tumor-bearing RIP1-Tag2 mice with pancreatic 
neuroendocrine tumors (PNET) treated for 5 weeks with the anti-angiogenic drug Sutent® 
showed an increased in life span (median survival of an additional 7 weeks) and marked 
decrease in tumor burden (>75% compared to control). They also reported that smaller tumors 
treated with Sutent® began to develop an invasive phenotype with tumor cells which invaded 
 
Figure 9 An overview of toxicities which can develop when using anti-angiogenic drug therapy including: bleeding and 
disturbed wound healing (a); gastrointestinal perforations due to disturbances to the intestinal villous capillaries (b); 
hypertension and reduced left ventricle ejection fraction (LVEF) (c); disturbances to thyroid gland homeostasis causing 
hypothyroidism and fatigue (d); kidney damage due to changes in osmotic pressure causing proteinuria and edema (e); skin 
toxicities due to changes in growth factor signaling cascades (f); leucopenia and lymphopenia (g) and thrombic events due 
to endothelial cell damage (h) (82). 
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surrounding tissues. This, however, was accompanied by no significant increase in lymphatic 
metastasis but an increase in tumor micro-metastases in the liver of the Sutent® treated mice 
when compared to control mice (23; 83). 
Another study by Ebos et al (84) reported that mice treated with short term Sutent® therapy (120 
mg/kg/day) for 7 consecutive days, either directly before or after intravenous tumor implantation, 
showed accelerated tumor metastasis and reduced survival when compared to control mice 
who received a dose of Sutent® which was considered the minimum effective tumor-inhibiting 
dose (continuously administering 40-60 mg/kg/day), as determined by a previous preclinical 
study (85).  
On the other hand, clinical data from more than 10,000 patients treated with anti-VEGF therapy 
reported that “it is unlikely that VEGF-targeted therapy accelerates metastasis” (23; 86). In 
addition, many sources have suggested that anti-angiogenic therapy may in fact help to prevent 
tumor metastasis, as it is believed that the process of metastasis is angiogenesis-dependent 
and may also be inhibited by anti-angiogenic drug therapy (87). 
Anti-angiogenic drugs 
Avastin® 
Avastin® is a recombinant humanized monoclonal anti-body which specifically targets the 
VEGF-A isoform of vascular endothelial growth factor. It effective binds and neutralizes human 
VEGF, preventing it from binding with its target receptors, VEGFR-1 and 2. Avastin® is 
composed of a full length, 149 kDa, antibody derived from an anti-VEGF mouse monoclonal 
antibody. It is metabolized and eliminated by the reticuloendothelial system and has no active or 
inactive metabolites (88).  
As previously discussed, Avastin® is not clinically-approved for the treatment of AMD, but is 
frequently used „off-label‟ for this indication in a dose of 1.25 mg (89). Avastin® is the first 
clinically-approved angiogenesis inhibitor and was originally approved as a first-line treatment 
for patients with advanced, metastatic, colorectal cancer, preferably in combination with 
fluoropyrimidine-based chemotherapy (90). In 2008, it was also approved for the treatment of 
unresectable, advanced metastatic or recurrent non-squamous non-small cell lung cancer 
(NSCLC) in combination with paclitaxel/carboplatin, and has received conditional approval for 
the treatment of breast cancer and glioblastoma multiforme (88; 91; 71). 
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For cancer treatment, Avastin® is administered intravenously in a dose ranging from 1 to 10 
mg/kg every two weeks. Avastin® is predominantly used in combination with chemotherapy, 
because it has been shown to increase the efficiency of treatment and improve progression free 
survival and response (90; 92; 93). It is hypothesized that by blocking VEGF signaling, Avastin® 
may help to transiently decrease blood vessel leakage in tumors, reducing VEGF-induced 
hemorrhaging and edema and the physiological effect of the tumor burden (71). This is believed 
to improve blood flow, increasing the bioavailability of chemotherapeutics in the tumor 
microenvironment, resulting in increased beneficial effects from chemotherapy treatment (71). 
A phase II clinical trial performed by Yang et al. studied the effects of Avastin® therapy on 116 
patients with treatment-refractory metastatic clear-cell renal cell carcinoma (RCC). Patients 
were either treated with a placebo, low-dose (3 mg/kg) or high-dose (10 mg/kg) Avastin® 
administered intravenously every 2 weeks (94). The high-dose treatment group showed 
significantly longer time to progression when compared to the placebo treatment group (4.8 vs. 
2.5 months). No life-threatening toxicities or deaths were reported. The high-dose treatment 
group showed side effects including: hypertension of any grade (36%) and grade 3 hypertension 
(21%, not controlled by one standard medication) and asymptomatic proteinuria with no renal 
insufficiency (64%). All these side effects were reversible after treatment was stopped. Grade 1 
and 2 haemoptysis was also seen in 2 patients in the Avastin® treatment group and in 2 patients 
in the placebo treatment group, no thromboembolic events were reported (94; 22). 
Sutent® 
Sutent® is a broad spectrum, small-molecule RTKI which targets VEGFR (particularly VEGFR-2) 
and other RTKs including PDGF and c-kit receptors (22; 95). Being a broad spectrum or 
multiple target RTKI, Sutent® interacts with a variety of other RTKs having potential „off-target‟ 
effects which may be at the origin of some of the side effects and toxicities associated with 
Sutent® therapy. It has been speculated that Sutent® may have an additional direct inhibitory 
effect on tumor cells by inhibiting one or more of their RTKs (96). Due to the fact that Sutent® 
primarily targets tumor vasculature, treatment may have additional effects on drug delivery to 
the tumor mass and result in sensitivity of specific vessels to the drug (96). 
Sutent® can be administered orally, frequently in a salt form referred to as sunitinib malate, due 
to the fact that it is a small molecule (molecular weight of 532 Da) which is mostly hydrophobic. 
These characteristics make Sutent® capable of passing through cell membranes where it can 
directly interact with the intracellular domain of receptors and intracellular signaling molecules 
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(16). Sutent®‟s bioavailability is not entirely understood, although it is known that its absorption 
occurs slowly and a steady-state concentration can only be achieved after 10-14 daily doses 
(97). Pharmacokinetic studies on animals have shown that at steady state, a minimum plasma 
concentration between 50 and 100 ng/ml of Sutent® and its primary metabolite (SU212662) are 
needed for pharmacological activity (98). The main route of elimination of Sutent® from the body 
is through fecal excretion (99; 16; 75). 
Sutent® is an anti-angiogenic and anti-cancer drug, and, as such, is approved for the treatment 
of multiple forms of cancer. Sutent® was clinically approved for the treatment of RCC and 
imatinib-resistant gastrointestinal stromal tumor (GIST) in 2006 (100; 101). More recently, in 
2010, the European Commission approved the use of Sutent® for the treatment of „unresectable 
or metastatic, well-differentiated pancreatic neuroendocrine tumors with disease progression in 
adults‟ (102). A phase III clinical study on metastatic RCC showed that Sutent® monotherapy 
was a more effective treatment option than interferon alpha immune therapy, which is the first 
line of therapy for RCC which is chemotherapy resistant (103).Typical treatment regiments for 
cancer patients includes oral administration of Sutent® in 12.5, 25 or 50 mg daily doses, on a 6-
week treatment cycle of 4-weeks on and 2-weeks off (100; 101). A study by Minkin et al. was 
aimed at developing a method to quantify the Sutent® plasma concentrations in patients treated 
with 25 mg/day on the 6-week cycle mentioned above. After 4 weeks of treatment, the steady 
state minimum concentration in these patients was reported to be 32 ng/ml (falling within the 
range predicted by the animal study discussed in the paragraph above) (104).  
In clinical trials, many patients develop a resistance to Sutent® therapy and it has become 
evident that this may be a limitation of Sutent® therapy. Most patients experience at least 
transient benefits from treatment; however, a small percent experience no benefits. A study by 
McDermott et al. examining the effects of Sutent® therapy on 637 tumor cells lines showed that 
only two of the lines were highly sensitive to Sutent® at 1 μM due to activated PDGFRα 
signaling, indicating that the other lines had already developed a resistance to the drug (105). 
Advanced in reversing drug resistance, however, are possible as the Researchers at the Van 
Andel Research Institute (VARI) studying the effects of Sutent® and its mechanism of action 
may have identified a way to reverse Sutent® resistance in clear cell RCC tumors. They found 
that these tumor cells are capable of developing Sutent® resistance through increased secretion 
of the protein interleukin-8 (IL-8), and that when Sutent® is administering in combination with IL-
8 neutralizing antibodies, the tumors cells were resensitized to Sutent® therapy (106).  
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In addition to being approved for the treatment of RCC and GIST, Sutent® has also been 
investigated in Phase II clinical trials for the treatment of breast cancer, non-small cell lung 
cancer, and neuroendocrine tumors. A summary of selected Sutent® clinical trials adapted from 
a review published by Adams et al. can be seen in Figure 10 (75). These studies show the large 
therapeutic potential of an anti-angiogenic RTKI, such as Sutent®, in the treatment of a variety 
of different forms of cancer.  
Enough evidence has supported the theory that anti-angiogenic drug therapy can provide a 
novel and effective form of therapy for cancer that it has become a standard form of therapy and 
is considered the fourth modality of cancer treatment after surgery, chemo- and radiation- 
therapy (23). 
First Author Patients Treated Sutent® Regiment Patient Response  
Motzer et al. (95) Cytokine-resistant mRCC 50 mg/d, 4 wk on, 2 wk 
off 
PR, 40%; SD ≥ 3 mo, 
27% 
Rini et al. (145) Bevacizumab-resistant 
mRCC 
50 mg/d, 4 wk on, 2 wk 
off 
PR, 16%; SD, 61%; 
reduction in tumor 
size 56% 
George et al. (150) Imatinib-resistant GIST 37.5 mg/d, continuous 
dosing 
SD in 13/17 (2 
unconfirmed PRs) at ≥ 
12 wk 
Morgan et al. (148) Imatinib-resistant GIST 
(before approval) 
50 mg/d, 4 wk on, 2 wk 
off 
CR, 0.7%; PR, 14%; SD, 
63% 
Sociniski et al. (149) Second- or third-line 
treatment of NSCLC 
50 mg/d, 4 wk on, 2 wk 
off 
Preliminary analysis: 
PR, 9.5%; SD at ≥ 8 wk, 
42.9% 
Miller et al. (147) Metastatic breast cancer 
that has failed to respond 
to anthracycline and 
taxane 
50 mg/d, 4 wk on, 2 wk 
off 
PR, 14%; SD at ≥ 6 mo, 
2% 
        
mRCC - metastatic renal cell carcinoma NSCLC - non-small cell lung cancer 
PR - partial response SD - stable disease CR - complete response   
 
Figure 10 Summary of clinical trials investigating the use of Sutent® in the treatment of various forms of cancer (75). 
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Photodynamic therapy 
The concept of using light as a form of therapy has existed since antiquity. Many ancient 
civilizations such as the Egyptians, Indians and Greeks performed a type of photodynamic 
therapy using natural photosensitizers found in psolaren-containing plants and sunlight to treat 
skin disorders such as psoriasis and vitiligo (107).  
Modern PDT utilizes a photosensitizing agent, most often a porphyrin-based compound, and 
light in the visual or near-infrared wavelengths. These photosensitizers (PSs) are activated 
when irradiated by light allowing them to react with oxygen in the environment creating highly 
reactive, short-lived singlet oxygen and reactive oxygen radicals, which causes local damage to 
the vascular endothelium and eventually results in vessel occlusion (65). Clinical applications, 
advantages and limitations of this therapy will be discussed before its mechanism of action and 
vascular effects are described in more depth. 
Clinical applications 
In addition to being used in the treatment of AMD, PDT is frequently used in the treatment of 
early stage cancer with good results and is considered an efficacious, simple, minimally 
invasive, repeatable form of therapy (40). PDT is used in the treatment of head and neck tumors 
(108), breast cancer (109), brain tumors (110), gynecological tumors (111), non-small cell lung 
cancer (112), bladder carcinoma (113), esophageal and skin cancers (including basal cell 
carcinoma (BCC) (114) and Bowen‟s disease) (115; 116; 117). PDT is also extensively used in 
the treatment of dermatological disorders including, but not limited to: acne vulgaris, photo 
rejuvenation, psoriasis, cutaneous lymphoma, viral warts and scleroderma (116).  
A multicenter study of a large number of patients with five-year follow up found that PDT 
treatment of patients suffering from BCC showed a success rate of approximately 95% in 
superficial BCC and 73-94% in nodular BCC (114). The recurrence rate of the superficial BCC 
was 22% (compared to 19% for other common forms of therapy) and 14% for nodular BCC 
(compared to 4% for other treatment forms which mainly include surgery) (114; 116)  
Advantages and limitations 
PDT can provide therapeutic benefits for many forms of cancer, skin disorders and AMD. The 
use of PDT in the treatment of cancer is advantageous over other forms of therapy (surgery, 
chemotherapy or radiation-therapy) due to the fact that it is relatively non-invasive, results in 
selective tissue damage and can be used to treat more than one lesion at a time (116). PDT 
results in relatively limited damage to healthy tissue (due to both selective localization of the PS 
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and localized irradiation), uses non-ionizing radiation and allows for relatively rapid recovery 
(116). In addition, PDT can be used in combination with other therapies (such as anti-
angiogenic drug therapies or chemotherapies) in hopes of achieving synergistic effects. 
Although PDT is relatively non-invasive, it can still result in some side effects. These can 
include: burns, swelling, pain and scarring of nearby tissues; skin and eye sensitivity to light; 
stenosis, and perforation of hollow organs (115). In addition it has also been reported to result in 
DNA damage including strand breaks, alkali-labile sites, DNA degradation and DNA-protein 
cross links, and possibly causes chromosomal aberrations, such as sister chromatid exchanges 
and mutations (65). Other shortcomings of PDT include the limitation of treatment depth due to 
the penetration of light. Activation of PS is necessary in order to initiate the cytotoxic activity of 
PDT, which limits treatment to lesions which are mainly superficial and can be directly 
illuminated or are reachable by an endoscope for illumination, such as skin and hollow organ 
cancers. In general, the penetration depth in tissue of the visible or IR light used in PDT ranges 
from several mm to a 1 cm (116). 
In addition to being limited by the penetration depth of light, PDT can also be limited by the 
revascularization of treated areas. PDT results in damage to the vascular endothelium, which 
causes increased vascular permeability as well as platelet aggregation, blood flow stasis, 
vasoconstriction and eventually vascular occlusion. This vascular damage induces inflammation 
and hypoxia, which in turn results in the activation of hypoxia inducible factors (HIF) and the 
expression of angiogenic and survival molecules, including VEGF (43). The activation of 
angiogenesis results in the revascularization of treated area, which is frequently accompanied 
by disease progression and the return of disease symptoms. A major limitation of PDT, 
therefore, is that its effects can be transient and re-treatment is frequently necessary. 
Mechanism of action 
The mechanism of action of PDT is dependent on three requirements: the localization of the PS 
in the malignant tissue resulting is selective tissue damage; the activation of the PS by light, 
followed by a series of energy transfers leading to the creation of reactive singlet oxygen 
molecules, and vascular and cellular damage induced by the singlet oxygen molecules leading 
to endothelial cell damage, blood flow stasis, and vascular occlusion. Each of these elements 
will be discussed in more depth in the following sections.  
27 
 
 
PS selective uptake and retention 
The „selectivity‟ of PDT depends on many factors including the drug, the drug carrier, the 
application of light, and the tissue properties (40). The first step to achieving selective tissue 
damage is to have selective PS uptake in the target tissue. In the case of AMD and cancer, 
increased permeability and leakiness of blood vessels can result in increased PS delivery. In 
addition, tumors may have increased expression of low density lipoprotein (LDL) and receptors 
such as albumin. This can increase delivery of hydrophobic PSs, which can be bound in a lipid 
core of lipoproteins, or hydrophilic PSs which can be transported by albumin. In addition, 
advanced cancers tend to have decreased lymphatic drainage and low pH environments, which 
can cause a decrease in the solubility of some porphyrins (40). 
Following selective uptake of the PS, selective retention is needed in order to localize tissue 
damage. Selective retention can be achieved through properties which are specific to the 
diseased tissue or through chemical manipulations, such as a PS which is targeted to a certain 
receptor selectively expressed on tumor cells or tumor endothelium (40).  
Due to its importance in regards to this research, the specific case of PDT treatment of the 
CNVs which develop in AMD will be addressed in more depth. A schematic of the macular 
region of the retina is shown in Figure 11 (40). The first layer of nerves below the macula 
consists of the photoreceptors, which are activated by light from above. Activated 
photoreceptors send a signal to the bipolar, horizontal, amacrine and ganglion cells for 
preprocessing before this signal is sent to the brain through to optic nerve. The retinal pigment 
epithelium (RPE) is a layer of „macro-phage-like‟, highly pigmented cells, which are located 
below the photoreceptors. Blood flow in the eye is supplied by the following vascular networks 
(shown in Figure 11, from top to bottom) (40). The retina is supplied with blood from the retinal 
arteries and veins (labeled RV in the figure), which flows into the retinal capillary network (Ret 
Cap) around the macula (the macula itself has no vascular network because this would impair 
vision). The Bruch‟s membrane is located below the RPE and receives its blood supply from the 
choroidal capillaries (Ch Cap) which are fed by the larger choroidal vessels (CV).  
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Closure of blood vessels in the retina must be very selective, because closure of the wrong 
vessels could result in vision loss. In particular, closure of the retinal capillaries must be avoided 
(40). This can partially be avoided due to a lower partial pressure of oxygen in the retinal 
circulation compared to the choroidal circulation and oxygen gradients created by 
heterogeneous oxygen supply and consumption across the retina (40). Cellular damage is also 
mostly localized to the vasculature due to limited leakage of PSs into surrounding tissue when 
light is applied relatively quickly following PS injection. Limited PS leakage results in limited 
damage to photoreceptors and the RPE. Limiting damage to blood vessels, however, is not 
enough, because selective close of the malignant CNVs is desired without closure of the 
choriocapillaries or larger choroidal vessels (40). This is partially achieved due to the fact that 
the larger choroidal vessels have a significantly higher amount of collagen in the vessel walls, 
which may provide some degree of vascular protection (40). Additionally, the malignant vessels 
may have higher expression of LDL and albumin receptors, resulting in increased uptake of 
PSs. This selectivity, however, is not completely achieved as significant closure of 
choriocapillaries is seen even up to one week after PDT-treatment (as can be seen in the non-
fluorescent part of the image shown in Figure 20) (40). 
PS excitation and energy transfer 
Following the localization of the PS, it must be irradiated by the proper wavelength of light in 
order to be activated to its excited state (PS*). In order to become excited, the PSs must absorb 
 
Figure 11 An overview of structure located in the macular region of the retina in eye (40).  
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energy from light in the form of photons. An absorption spectrum describes the probability that 
light will be absorption as a function of wavelength for a given molecule or the probability that an 
incident photon will induce an energy level change (40). The absorption spectrum for 
Visudyne®, the PS used in these experiments and in the treatment of AMD, can be seen in 
Figure 17 (118).  
Following excitation due to the absorption of a photon, the PS undergoes a series of energy 
transfers, which finally result in the production of a reactive singlet oxygen molecule. These 
energy transfers can be described using a Jablonski diagram, which shows the different energy 
levels of an electron and describes the possible transitions between them. A typical Jablonski 
diagram can be seen in Figure 12 (119). When a photon is absorbed by the PS, it becomes 
excited by making an energy transition from the ground singlet state (S0) to a vibrationally 
excited level of the singlet excited state (S1). The process of absorption is extremely fast, taking 
only 10-15 seconds. The excited PS (PS*) then undergoes internal conversion (IC) (taking ~10-12 
seconds), to the „ground‟ S1 state, from which a variety of different energy transfers can take 
place. In order for PDT to result in cellular damage, the PS* must then undergo intersystem 
crossing (ISC), a non-radiative change between electronic states with different multiplicity (e.g. 
a transition from S1 to T1, due to the higher energy of S1, the transfer would be to the higher 
 
Figure 12 A Jablonski diagram showing the different energy levels of an electron and the possible energy 
transitions between them (119). 
 
 
30 
 
energy state of T1 and would relax to ground state through IC). After undergoing ISC, the T1 
state PS can transfer its energy through a chemical reaction (e.g. S1 chemical reaction by 
rearranging itself, connecting to another molecule or disassociating), exchange energy with a 
nearby molecule causing it to become excited to the singlet state, or it can relax through internal 
conversion to return to the S0 state (40). In the situation of PDT, the triplet state PS will react 
chemically with molecules in the environment to generate reactive singlet oxygen.  
There are three main pathways through which the triple PS can chemically react, as shown in 
Figure 13 (40). The first pathway (referred to as type II reactions) is an energy transfer to an 
oxygen molecule or to a substrate molecule. An energy transfer to ground state oxygen 
generates a singlet molecular oxygen, which can then react with the PS (bleaching it) or oxidize 
a nearby biomolecular target. The second pathway is a hydrogen atom exchange between the 
PS and a substrate molecule which can react with O2, forming peroxide radicals as intermediary 
molecules in the process of oxidizing the substrate molecule. The final pathways is an electron 
transfer between the PS and a substrate molecule, generating radical ions which, in 
combination with O2, can cause other oxidizing reactive intermediates, such as superoxide 
radical anion, H2O2, or hydroxyl radicals which are highly reactive. The second and third 
 
Figure 13 Overview of the photo-oxidative reactions available to the triplet state photosensitizer (
3
PS) which result in the 
generation of a sensitized biological substrate molecule (M) (40). 
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pathways are known as type I reactions. Type II reactions require oxygen in the first step, while 
type I reaction require oxygen farther down in the chain of energy transfers. The photosensitizer 
Visudyne® primarily interacts through type two reaction. The singlet oxygen which is generated 
can react with proteins, lipids and nucleic acids to create free radicals leading to auto-oxidation 
and breakdown of these molecules (120). Vascular damage is highly localized due to the fact 
that singlet oxygen is highly reactive, and will either react very quickly or be quenched, so that 
distant reactions are only a fraction of nanometers away from the PS (40).  
Cellular effects 
Following the activation of the PSs and the generation of reactive singlet oxygen molecules, 
these molecules can cause tissue damage through cellular, vascular and immunological effects 
(40). Tissue damage depends on the tissue, the sensitizer and the conditions of PDT applied 
(i.e. time between drug and light application, the drug delivery system which affects the 
localization of the PSs during therapy, and factors such as the quantity of drug or light applied). 
PSs mainly target endothelial cells through either the mitochondria (for BPD-MA based PSs 
including Visudyne®) or through the lysosome and plasma membrane causing cell death 
through necrosis or apoptosis (40). Water soluble PSs, which localize in the lysosomes, 
normally cause cell death through necrosis and apoptosis due to the release of cathepsins and 
caspase 3. Mitochondrially-localized PS‟s, however, mainly cause cell death through apoptosis. 
It is generally more desirable to induce vascular damage through apoptosis than through 
necrosis, because it requires lower drug and light doses and may be easier to manipulate than 
necrotic cell death, allowing for more selective tissue damage (40). 
PDT causes peroxidation in organelles where the PS has accumulated, which can result in 
organelle membrane disruption, changes in membrane potential or damage to membrane 
proteins (40). Cells partially damaged by PDT will activate rescue responses including the 
release of heat shock proteins, glucose-regulated proteins and heme oxygenase (40; 121). PDT 
can also affect cell surface receptors inducing the release of cytokines, which may have 
additional effects on the immune response (40).  
Mitochondrially-localized PSs, such as the one used in the experiments for this study, 
Visudyne®, mainly cause cell death through apoptosis. An overview of the interactions which 
result in apoptosis can be seen in Figure 14 (40). Overall, it is believed that these PSs are 
capable of inducing the loss of mitochondrial membrane potential by opening a large 
conductance channel called the mitochondrial permeability transition pore complex (PTPC) (40). 
32 
 
This may result in the release of cytochrome-c into the cytosol, where it can react with 
apoptosis-activating factor-1 (APAF-1) and ATP to form a multi-protein complex called an 
apoptosome (122). This complex activates caspase 9, which activates caspase 3, which in turn 
activates caspase 6. Caspase 3 cleaves proteins involved in repairing damaged DNA (poly-
ADP-ribose polymerase and DNA-PK) as well as activating a molecule (CAD) known to cause 
DNA damage. Caspase 6 cleaves the lamins of the cell‟s nucleus causing nuclear breakdown 
and interacts with other molecules know to be involved in apoptosis such as SHREBs, Gelsolin, 
caspase 7, caspase 9, MDM2, GAS2, Fodrin, FAK and more (40). 
Another mechanism of apoptosis is through the activation of the cell surface “death receptors” 
such as TRAIL (TNF-related apoptosis-inducing ligand), FAS and TNFR1 (tumor necrosis factor 
receptor 1) (40). In this pathway, also shown in Figure 14, activation of these receptors will 
result in adopter proteins such as FADD (FAS associated death domain) to bind to other 
proteins in the cytosol. The complex they create induces the release of caspase 8, which 
causes the release of caspase 3, and cleaves Bid to create truncated Bid (t-Bid), which moves 
to the mitochondrial membrane to help release cytochrome-c. Cytochrome-c is also involved in 
apoptosis through indirect interactions with the caspases mentioned above (40; 122; 123; 124). 
 
Figure 14 An overview of the cellular pathways which result in cell death through apoptosis, the mechanism of cell death 
mainly achieved by mitochondrially-localized photosensitizers such as Visudyne® (40). 
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PDT-induced vascular effects 
In certain indication, including the treatment of AMD, the main aim of PDT-treatment is to induce 
vascular damage. In the context of this study, it is therefore also important to examine the 
vascular effects of PDT. Predominantly vascular effects of PDT can be achieved by specifically 
selecting the conditions and PS used to perform PDT. The first visible vascular effect of PDT is 
vasoconstriction, which can be seen immediately following the application of light and up to 
several hours follow treatment (40). Early damage following PS injection and illumination has 
mostly been observed in the endothelial and sub-endothelial cells. Early changes to endothelial 
cells can be seen in the luminal surface, cytoplasmic microtubules, cytoskeletal proteins, and 
mitochondria. These changes cause the endothelial cells to retract, losing their tight junctions 
with neighbor cells and exposing the basement membrane. An overview of the vascular effects 
of PDT can be seen in Figure 15 (40). This figure shows the healthy vessel wall (a), the 
endothelial cells which have retracted following PDT damage (b), and the activation of platelets 
and polymorphonuclear leukocytes due to exposure of the basement membrane, which 
increase the release of eicosanoids, resulting in platelet aggregation on the basement 
membrane of the vessel (c) (40).  
 
PDT causes polymorphonuclear leukocytes to attach to vessel walls, which results in a change 
in the release of biochemicals, such as eicosanoids thromboxane and leukotriene B4 and C4 
(40). These factors disturb the balance between aggregation/disaggregation of platelets and 
vasodilation/vasoconstriction processes in blood vessels. These imbalances are counteracted 
 
Figure 15 Overview of the mechanism by which PDT induces vascular damage resulting in blood flow stasis (40). 
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by increased smooth muscle activity resulting in vasoconstriction. Platelet aggregation, 
combined with vasoconstriction, results in the formation of a plug, which is then stabilized by 
fibrin (Figure 15C). The retraction of endothelial cells and biochemical changes initially causes 
an increase in vessel permeability and leakage, before finally leading to blood flow stasis and 
vascular occlusion (40). 
Another mechanism leading to vascular occlusion is through PDT damage to membrane lipids. 
This causes the release of arachidonic acid, which initiates a biochemical cascade ending in the 
release of thromboxane, a vasoconstrictor. This, in addition to increased interstitial pressure due 
to increase vascular leakage, also contributes to blood flow stasis and vascular occlusion (40). 
Visudyne® 
Visudyne® (Verteporfin for injection; Benzoporphyrin Derivative Monoacid Ring A (BPD-MA); 
Novartis AG), is the photosensitive molecule clinically used in the treatment of AMD and other 
eye disorders including pathological myopia, and presumed ocular histoplasmosis (69). 
Visudyne® is composed of a semisynthetic mixture of two porphyrin regioisomers shown in 
Figure 16 (120; 65).  
 
 
 
 
 
 
 
 
 
The quantum yield for the production of singlet oxygen by Visudyne® is 0.76 in methanol (125) 
(meaning that approximately 8 out of 10 photons absorbed by Visudyne® result in the production 
of a singlet oxygen molecule). Approximated 500,000 singlet oxygen molecules can be 
produced by a Visudyne® molecule in one second (120). Desirable qualities for a PS include a 
 
Figure 16 The chemical structure of the two isomers which make up Visudyne® (65). 
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high quantum yield and a long-lived triplet state (40). The absorption spectrum of Visudyne® in 
ethanol and oxyhemoglobin in phosphate buffered saline is presented in Figure 17. Visudyne® 
has two absorption peaks, the Soret band at 420 nm and the Q-band at 689 nm. In clinical 
applications, the absorption peak at 689 nm is used to excite Visudyne® due to the increased 
penetration depth of red light and its decreased interaction with endogenous molecules. If the 
420 nm absorption peak were used, oxyhemoglobin would have a strong interference with the 
excitation of Visudyne® as it has a large absorption peak at this wavelength (shown in Figure 
17). In addition, the higher excitation peak is located in a range of wavelengths which have been 
shown to be safer for the retina (120). For the laboratory procedures in this study, however, the 
420 nm absorption peak is used to excite Visudyne® molecules. 
 
 
 
 
 
 
 
 
 
 
 
After being intravenously administered, Visudyne® is primarily transported in the plasma by 
lipoproteins and exhibits a bi-exponential elimination, with a terminal elimination half-life of 
approximately 5-6 hours (65). Visudyne® is metabolized by human liver S9 and human liver 
microsomes into a „diacid‟ metabolite (120). Exposure and maximal plasma concentration are 
proportional to the administered dose and range between 6 and 20 mg/m2 (65). The primary 
route of Visudyne® excretion is through the bile and feces, due to its being a highly lipophilic 
molecule with a high molecular weight (120). The safety and efficacy of this drug has only been 
 
Figure 17 The absorption spectra for Visudyne® in ethanol and 
oxyhemoglobin in phosphate buffered saline, showing an absorption peak 
for Visudyne® at 420 nm which overlaps an absorption peak for 
oxyhemoglobin and a second absorption peak for Visudyne® at 689 nm 
(118).  
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demonstrated for a 2 year period following treatment. Common side effects and complications 
include: light sensitivity; severe decrease of vision ( 4 lines) within 1 week, and extravastion of 
Visudyne® at the injection site causing pain, inflammation, swelling and discoloration (65).  
Comparative study of PDT and anti-angiogenic treatment of AMD 
A study was conducted by Brown et al. to compare the effects of treating AMD with PDT or anti-
angiogenic drug monotherapies (126). Patients primarily suffered from classic, subfoveal CNVs 
and had not been previously treated with either form of therapy. Treatment was administered to 
three randomized groups receiving either: Visudyne®-PDT plus a fake intravitreal injection or 
non-active PDT plus monthly intravitreal injection of Lucentis® at a low- or high-dose (0.3 mg or 
0.5 mg) (423 patients total, 143 PDT, 140 in each of the 2 Lucentis® groups). The need for 
repeat PDT treatment (real or non-active) was examined every 3 months using fluorescein 
angiography. 
The effects of treatment were examined from months 12 through 24 in terms of the percentage 
of patients losing <15 letters from baseline visual acuity (12 month primary efficacy outcome 
measure), percentage gaining ≥15 letters from baseline, mean change over time in visual acuity 
scores and lesion characteristics monitored through fluorescein angiography. 
The results at 12 and 24 months showed an increase in visual acuity for the Lucentis®-treated 
group which was statistically significant and clinically meaningful when compared to PDT-
treated patients: approximately 90.0% of Lucentis®-treated patients had lost <15 letters from 
baseline compared to 65.7% of PDT-treated patients; 34% to 41.0% had gained ≥15 letters 
compared to 6.3% of PDT-treated patients; and, on average, visual acuity was improved from 
baseline by 8.1 to 10.7 letters compared to a mean decline of 9.8 letters in PDT-treated group) 
(126). In addition, the Lucentis®-treated group showed favorable changes in the anatomic 
characteristic of the lesion compared to the PDT-treated group. Overall, both treatment groups 
showed the same rate of serious ocular and nonocular adverse events (126). 
Clinical study on combination therapy for the treatment of AMD 
Due to the fact that PDT is frequently accompanied by revascularization of the treated area 
resulting in limited treatment benefits, the use of anti-angiogenic drug therapy in combination 
with PDT has become a popular idea for improving the efficiency of therapy. One particular 
study examining the benefits of combination therapy is described below.  
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The study was conducted to assess the outcome of patients with AMD treated with combination 
Visudyne®-PDT and Avastin® anti-angiogenic drug therapy (127). The study included 1196 
patients with CNVs due to AMD who received at least one combination treatment of 1.25 mg 
intravitreal Avastin® within 14 days of Visudyne®-PDT. After the initial combination treatment, 
patients received an average of 0.6 additional Visudyne®- PDT re-treatments and 2 Avastin® re-
treatments over an average period of 15 months. 
At the 12 month check point, 82% of patients (578/701) had stable or improved vision (loss of 
<3 lines or a gain in visual acuity), 36% (255/701) improved by ≥3 lines, and 17% (121/701) 
improved by ≥6 lines. By 12 months, patients gained an average of approximately 1.2 lines (6 
letters) of visual acuity from their baseline. Patients who were treated for the first time gained 
significantly more visual acuity by month 12 (+8.4 letters) compared with those who had been 
previously treated (+2.4 letters; P<0.01). Most of the serious adverse events (26/30) were 
considered to be unrelated to any study treatment; however, there were 3 ocular events related 
to Avastin® alone and 1 ocular event was related to combination Avastin® and PDT treatment. 
Combination therapy with PDT and Avastin® led to vision benefit for most patients, particularly 
those who were being treated for the first time. It should also be noted that the need for 
retreatment was lower than reported for either monotherapy alone (127). 
Chicken Chorioallantoic Membrane (CAM) model 
The chicken embryo chorioallantoic membrane (CAM) model is used in the experiments for this 
study in order to test anti-angiogenic agents alone and in combination with PDT. In recent 
years, the CAM model has become very popular and is now commonly used in the study of 
angiogenesis (29). This model provides a natural, in vivo environment of angiogenic blood 
vessels with all the complex host interactions on which angiogenic compounds can be tested 
(29). The main advantage of this model is its direct exposure to cells, tissues, biomaterial, drugs 
or other forms of therapy in order to determine their effects on angiogenesis (29). 
The CAM is a membrane which forms around the embryo through the fusion of two of the four 
extraembryonic membranes, the chorion and the allantois, on embryo development day (EDD) 4 
(29). It provides some basic physiological functions needed for the embryo to survive including: 
respiratory functions through the exchange of oxygen and carbon dioxide with the environment; 
absorbing calcium from the eggshell; providing a reservoir for waste products of the embryo 
(initially urea then mostly uric acid), and absorption of albumin by the allantois (29). In order to 
perform these functions, the CAM develops as a highly vascularized membrane in direct contact 
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with the eggshell. An image of a chicken egg and the CAM can be seen in Figure 18. In the 
following section, other common angiogenesis models will be discussed and the particular uses 
and advantages of the CAM model in the study of angiogenesis will be addressed.  
  
 
 
 
 
 
 
 
 
 
Angiogenesis models 
There exist many alternative models, both in vivo and in vitro, which can be used to study 
angiogenesis. The process of angiogenesis involves disruption of basement membrane, cell 
migration, cell proliferation and tube formation, all of which can be examined individually in vitro. 
In vitro models can provide a lot of information, but they are limited in their ability to simulate 
more complicated pathways and interactions involved in biological processes, creating a need 
for in vivo models as well (29). 
Some common in vitro angiogenesis models include: endothelial cell culture assays, endothelial 
cell proliferation assays (128), endothelial cell migration assays (chemokinesis and chemotaxis) 
(129), endothelial cell tube formation assays (130), endothelial apoptosis and viability assays 
(trypan blue) (131), angiogenesis factor-transfected endothelial cell lines and endothelial cell 
outgrowth or organ assays (aortic ring assay (132) and chick aortic arch assay (133)). 
There also exist many alternative in vivo angiogenesis models including: transparent chamber 
models (rabbit ear chamber (134), hamster cheek pouch (135) and dorsal skin chamber (136)), 
 
Figure 18 Image of a chicken egg showing the highly vascularized CAM 
above the embryo. 
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corneal micropocket assays (rabbit and rodent) (137), and various implants assays 
(subcutaneous injection using sodium alginate, subcutaneous disc implant made out of polyvinyl 
foam, matrigel plug (138) and sponge implants (139)). 
Each of these models has unique advantages and disadvantages which make them desirable 
for use in different applications. The CAM model is particularly well suited to the research 
conducted for this study, because it is an inexpensive in vivo model which allows for relatively 
high throughput testing of multiple drugs at different concentrations. The CAM model combines 
the advantages of having an in vivo system without carrying the costs and regulatory issues 
normally associated with animal testing. In addition, due to the nature of the CAM model, test 
substances can be placed directly on the membrane and the effects of treatment can be directly 
visualized in real time. 
CAM as an angiogenesis model 
There exist two variations of the CAM model: the in ovo and the ex ovo models. These studies 
were done using the in ovo model. In the in ovo model, the eggs is left to develop inside of the 
eggshell and the CAM is accessed by creating a hole in the eggshell, referred to as windowing, 
and allowing the membrane to drop and develop detached from the eggshell in a certain area 
(29). This method provides the advantage that it maintains a more physiological environment for 
the development of the membrane; however, it is limited due to the fact that only a small portion 
of the CAM is accessible, and there is an increased chance that the membrane may not drop 
properly, limiting access to the CAM at the time or in the manner desired (29). 
The alternative CAM model is the ex ovo method where CAM is grow in a shell-less 
environment by transferring the contents of the eggs to an artificial eggshell container after 72 
hours of incubation. This model allows for a greater area of the membrane to be viewed and 
experimented on, but provides a less physiologic environment for the development of 
vasculature (29). Embryos which develop in the shell-less environment normally develop to be 
smaller, when compared to in ovo embryos, and frequently die before coming to full term (29). 
In addition to the in ovo and ex ovo models, there are many other variations in the methods 
used for experimenting on the CAM. These include variations in protocol (when and how long 
substances are applied and the vehicle used to administer the test substance). In literature, the 
application of drugs can range anywhere from EDD3 to 15 (29). The CAM vasculature grows 
rapidly until EDD9, so it is important to apply drugs before this time in order to examine the 
response of the rapidly-growing or angiogenic CAM. A previous study conducted in this 
40 
 
laboratory identified the ideal time for testing the effects of angiogenic agents on the naturally-
developing CAM membrane to be between EDD7 and 9 (140). 
Application vehicles used to administer test substances vary greatly and can include: methyl 
cellulose discs; Elvax™ polymer; matrigel; agarose gels (collagen gel inside parallel nylon 
meshes); gelatin sponges; filter discs (Millipore discs soaked in the solution); plastic cover slips 
(Thermanox cover slips onto which the stimulant has been dried); rings composed of silactic, 
Teflon or glass; flooding the CAM surface; direct inoculation into the cavity of the allantoic 
vesicle, or direct application of cells and tissues (29). 
Common procedures include placing the test substance on the CAM during early development 
(EDD7 through 10) and examining the reaction after at least 2 days of incubation. Features 
which are commonly examined after treatment include vessel density, new vessel formation, 
vessel tortuosity, vessel disorganization, characteristics of vessel branching, and the size, area 
and number of avascular zones (29).  
In addition, the CAM is also particularly well suited for studying the treatment of AMD, due to the 
fact that both the CAM and the retina are highly vascularized membranes. This can be seen by 
a study comparing leakage in the CNVs of the human eye to leakage in the small blood vessels 
of the CAM (40; 141). PS leakage is very important to treatment of AMD, because high levels of 
leakage can result in damage to areas of the retina which are not being targeted for treatment 
resulting in vision loss (40). This study showed strong localized leakage of fluorescein in the 
human eye over time, which is typical of aggressive „classical‟ CNVs. Similar leakage was seen 
when the CAM was injected with a different water soluble dye. Images from these experiments 
can be seen in Figure 19 (40; 141), with images of dye leakage from the human eye shown of 
the left and the CAM shown on the right (time elapsed after injection increases from top to 
bottom images) (40; 141). These images show similar leakage properties in the human eye and 
in the CAM model, indicating similar pharmacokinetics.    
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Figure 19 Leakage of a fluorescent dye from the human eye (on the left) and the CAM vasculature (on the 
right) used to simulate photosensitizer leakage. Images progress with time from top to bottom, showing 
similar leakage of dye from the vasculature over time for the two models (40).  
 
 
Figure 20 Efficiency of blood flow stasis and vessel closure in the human eye following PDT (shown on the 
left) and in the CAM membrane (shown on the right, 40 seconds before PDT, a minute and a half into PDT and 
24 hours following PDT) (40). 
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Similarly, blood flow stasis efficacy was also compared between the human eye and the CAM 
one week following Visudyne®-PDT (40; 141). Figure 20 on the left shows images of the human 
eye one week following Visudyne®-PDT (40). The dark spot in this image shows the macular 
region where the leakage of the CNVs has been stopped and leakage of the partially closed 
choriocapillaries has been decreased due to treatment. The images on the right of Figure 20 
show the CAM before, during and 24 hours following Visudyne®-PDT (40). These images show 
a dark spot on the CAM which is similar to the one seen following the clinical treatment of the 
human eye, indicating similar blood flow stasis in irradiated areas. 
Image-processing quantification programs 
Images of the CAM‟s vascular morphology following therapy are obtained through fluorescent 
angiography. These images are processed using two different macros written in ImageJ (with 
the help of existing plug-ins). One of the programs analyzes the inhibition of the naturally-
developing CAM due to anti-angiogenic drug therapy and the other quantifies vascular regrowth 
following PDT. Both programs were developed in this laboratory (The Medical Photonics Group, 
EPFL) specifically for this type of application. For more information on these programs the 
following two papers can be referenced (140; 142). Both of these programs will be briefly 
described in the following sections. 
Quantification of inhibition of the naturally-developing CAM 
To study the effects of anti-angiogenic compounds on the developing CAM, drugs are topically 
applied in a polyethylene ring on EDD7 and 8. On EDD9, the results of treatment are visualized 
through fluorescence angiogram.  
A flowchart giving an overview of the first image-processing program is shown in Figure 21 
(140). Figure 21A shows the original 16-bit image of the CAM vasculature, which is obtained 
from the fluorescence angiogram. The image is first put through an “a posteriori” shading 
correction filter, which corrects for inhomogeneities in the fluorescence excitation intensity 
(Figure 21C). This is followed by the removal of noise by a Fast Fourier Transform (FFT) band-
pass filter, which removes isolated single pixels and large “island-like” structures consisting of 
more than 90 pixels. From this point, the program runs two phases of analysis in parallel and 
superimposes the results onto each other to create the final skeletonized image of the 
vasculature. The first phase of processing extracts the main vessels through a threshold filter. 
The noise of this image is removed through a despeckle process, which removes individual 
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pixels, and a FFT band-pass filter removing islands of connected pixels less than 40 pixels in 
size. The result of this „first phase of processing can be seen in Figure 21B.  
In the second phase of processing, small vessels and capillaries are extracted from the image 
shown in Figure 21C using a rolling ball background filter. This is followed by a Laplacian filter 
(the result of which is shown in Figure 21D) and a Guassian filter. Part of the results from the 
Laplacian filter (-SD/2 to +SD/2) are used to generate an 8-bit image with a threshold put 
between 0 and 100. “Islands” of pixels less than 200 pixels are removed to produce the final 
image from the second phase of processing which can be seen in Figure 21E. The final 
skeletonization of the vasculature is generated by superimposing the images from the two 
phases of processing, and can be seen in Figure 21F. The final image shows all connections 
 
Figure 21 Overview of the image-processing program used to quantify the effects of treatment on the CAM's vascular 
network. (A) the original 16-bit image, (B) the original image after the “first phase threshold” to extract the main 
vessels, (C) the image after “a posteriori” shading correction filter, (D) the image following the second parallel phase of 
processing after application of the Laplacian filter, (E) the image converted to an 8-bit image, (F) the skeletonized 
version of the image, (G) histogram of non-vascularized meshes/mm
2
 corresponding to the image. Image size: 
1.4x1.2mm (140).  
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between vessels and capillaries, and capillaries and capillaries in the form of single pixel 
connecting lines. A morphology binary connectivity plug-in can be applied to determine the 
number of connected skeleton pixels.  
Before quantification, the angiogram is divided into 9 equal areas to be processed individually 
so that unfocused parts of the image can be removed. The program returns a skeletonized 
version of the vasculature, a „potential hypoxia map‟ and parameters describing the degree of 
vascular inhibition.  
Quantification of vascular regrowth following vaso-occlusive PDT 
To study the effects of vascular regrowth on PDT-induced angiogenesis, Visudyne®-PDT is 
performed on the CAM on EDD11. Combination therapy is performed by topically applying the 
desired drug directly following PDT and again 24 hours following PDT, while control (or PDT 
only) experiments are followed by the application of physiological water. The effects of these 
treatments are then visualized on EDD13 using a fluorescence angiograms. The ImageJ macro 
can be used to quantify the vascular regrowth, vessel density and architecture (142). 
 
 
 
 
 
 
 
 
 
 
 
A flowchart of the image-processing program described below can be seen in Figure 22 (143). 
The program also begins with the 16-bit image obtained from fluorescence angiograms. Three 
Figure 22 Overview of image quantification process (143). 
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points, manually inputted by the user, are used to determine the boarder of the treated area 
marking a circular region of interest. The macro then automatically generates 3 concentric 
circles, with identical widths, inside the original circle. The outermost circle is referred to as area 
4 and is the first zone to be revascularized, while the innermost circles is referred to as area 1 
and is the last to be revascularized. 
Once the program has marked the different areas of regrowth, noise is removed from the image 
using a despeckle process followed by a Gaussian filter. This is followed by a FFT band-pass 
filter, which removes all single pixels and large “island-like” structures more than 90 pixels in 
size. From this point two parallel phases of processing are run in parallel, the results of which 
are superimposed on each other to generate the final skeletonized image of the vasculature. 
The first phase of processing is used to isolate the main blood vessels. This is achieved through 
the application of a grey threshold value, which is empirically set at the mean grey value of the 
histogram + ½ SD. Isolated pixels are then removed using a despeckle process followed by the 
removal of small “islands of connected pixels” containing less than 40 pixels per “island”. 
The second phase of processing is used to isolate small vessels and capillaries. This is 
achieved by the application of a rolling ball background filer, followed by a Laplacian filer. A part 
of the results from the Laplacian (-SD/2 to +SD/2) are removed and transformed into an 8-bit 
image with a threshold set between 0 and 100. “Islands” less than 300 pixels are then removed. 
The skeletonization of the vasculature is then created by superimposing the results of these two 
phases of processing. The skeletonization shows all connections between vessel and 
capillaries, and capillaries and capillaries as single pixel connecting lines. The morphology 
binary connectivity plug-in can be used to determine the number of connected skeleton pixels. 
The program returns a skeletonized version of the vasculature, a „potential hypoxia map‟, and 
parameters describing the degree of vascular regrowth.  
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Materials and Methods 
The research conducted for this study utilizes two different experimental platforms involving the 
chicken embryo CAM model. The first experimental platform is the investigation of the effects of 
anti-angiogenic drugs on the physiologic angiogenic state of the developing CAM (EDD7-9). 
The second platform investigates the effects of anti-angiogenic drugs on the angiogenic state 
induced through vascular damage due to PDT on the mature CAM vasculature (EDD11-13). 
The materials and methods provided here are based on the material and methods published in 
previous articles from The Medical Photonics Group (140; 142). 
Materials and chemicals 
This study is based on the investigation of two anti-angiogenic drugs, Avastin® and Sutent®. 
Avastin® (bevacizumab) is purchased from Genetech (San Fancisco, USA) and Sutent® 
(sunitinib) is purchased from Pfizer Inc. (New York, USA). Visualization of blood vessels is 
achieved through fluorescent angiography using fluorescein isothiocyanate dextran (FITC-
Dextran, 20 kDA, 25 mg/ml), which is purchased from Sigma-Alrich (Buchs, Switzerland). India 
ink purchased from Pelikan (Witzikon \Switzerland) is injected into the extra-embryonic cavity to 
increase contrast during fluorescent angiography by blocking additional fluorescence from the 
embryo. A 0.9% NaCl solution, which is purchased from Bichsel AG (Interlaken, Switzerland), is 
used as a solvent to create dilutions for both drugs or alone as a control. Chicken embryos are 
purchased from AnimalcoAG (Staufen Switzerland). In order to perform PDT, the 
photosensitizer Visudyne® is acquired from Novartis Pharma, Inc. (Hettlingen Switzerland, the 
liposomal formulation of verteporfin (144)) and filtered through a sterile cellulose acetate 
membrane (0.8 μm pores, Renner GmbH, Darmstadt, Germany). Laboratory wrapping film used 
to cover the eggs protecting them from dehydration and possible contamination is purchased 
from Parafilm® (Pechiney, Menasha, USA). Injections into the CAM‟s vasculature are achieved 
using a Microliter™ syringes equipped with 33-guage metal HUB (N) needles from Hamilton 
(Reno, USA). Injection of india ink under the CAM is achieved using a sterile 5 mL Luer 
purchased from Codan Medical Aps and sterile 23-guage neolus needle purchased from 
Terumo® (Leuven, Belgium).  
The in ovo CAM model 
Fertilized chicken eggs are received from Animalco AG (Staufen, Switzerland), labeled and 
placed into a hatching incubator with a relative humidity of 65% and a temperature of 37o C. 
Incubators are equipped with an automatic rotator (Savimat, Chauffry, France). Eggs are 
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automatically rotated by the incubator until EDD3, when a hole of approximately 3mm in 
diameter is opened in the narrow apex of the shell using sterilized tweezers. The hole is then 
covered using Scotch® Magic™ transparent adhesive tape to prevent dehydration or 
contamination. When topically applying compounds to the CAM, a polyethylene ring (diameter 5 
mm, wall thickness 0.5 mm, height 1 mm) is placed on the surface and the drug is deposited 
inside the ring. These rings are cut from Pasteur pipettes purchased from Copan (Brescia, Italy) 
in sterile conditions. In order to visualize the CAM vasculature or perform PDT, the egg is 
placed under an epi-fluorescence microscope and the protocol described below is followed. 
When the egg is finished undergoing treatment, it is covered with Parafilm® and returned to the 
incubator in a static position until a new treatment protocol is needed. 
Microscope and image acquisition 
Visualization of the CAM‟s vasculature and light irradiation during PDT are achieved with an epi-
fluorescence Eclipse 600 FN microscope with Nikon objectives (Plan Apo 4x/0.2, working 
distance: 20mm or Plan Fluor 10x/0.3, working distance: 16 mm). A 100 W high pressure Hg-
arc lamp (Osram, GmbH, Ausburg, Germany) is used to illuminate specimens. Light doses 
applied during PDT are measured using a calibrated Filed-Master GS power meter (Coherent, 
Santa Clara USA) and can be adjusted using neutral density filters. While performing PDT, a 
BV-2A filter set (λex = 420 ± 20 nm, λem ˃ 470 nm, Nikon, Japan) is used in order to select for the 
appropriate excitation and detection wavelengths of Visudyne®. In order to visualize vasculature 
by fluorescent angiography, excitation light is passed through a band-pass excitation filtered 
(470 ± 20 nm) and emission light is passed through a long-pass emission filter (λ ˃ 520 nm). 
Fluorescence images are taken using an F-view II 12-bit monochrome Peltier-cooled digital 
CCD camera being run by „analySIS DOCU‟ software from Soft Imaging System GmbH 
(Munster, Germany). 
Inhibition of developmental angiogenesis in the CAM 
For experiments examining the response of the developmental CAM to topical application of 
drugs, the hole in the eggshell is increased to a diameter of approximately 3 cm on EDD7 
providing access to a portion of the CAM. Twenty micoliters of the appropriate drug is then 
topically applied in the polyethylene ring on EDD7 and EDD8. Fluorescence angiograms are 
taken approximately 48 hours following the first drug application in order to visualize the 
response of the CAM to the test compound. Fluorescence angiographies are performed through 
i.v. injection of 20 μl of FITC-dextran (20 kDa, 25 mg/ml) into one of the main blood vessels of 
the CAM (diameter of ~200μm) and injection of a known light absorber, India ink, into the extra-
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embryonic cavity directly below the topically treated area of the CAM. Light from an Hg-arc lamp 
filtered for excitation wavelength of 470 ± 20 nm and with a long-pass emission filter (λ ˃ 520 
nm) is used for illumination during the florescence angiography. Images are stored in a 16-bit 
TIF file and are later analyzed using the image-processing software previously described. Data 
points in the graphs provided in the results section represent the average of measurements 
from at least five embryos, with four different areas of 1.4 x 1.12 mm2 (taken with the x10 
objective) being analyzed per embryo. 
Visudyne®-photodynamic therapy 
For experiments where PDT is performed, the hole in the eggshell is increased to a diameter of 
approximately 3 cm on EDD11. Twenty μl of Visudyne is intravenously administered and given 
one minute to evenly distribute in the circulating blood. The CAM is then irradiated with a light 
dose of 20 J/cm2 (λex = 420 ±20 nm). The irradiation area is limited to 0.02 cm
2 using an optical 
diaphragm and a polyethylene ring used for topical drug application is placed around the 
irradiated area. Twenty micoliters of physiological water is topically applied within the 
polyethylene ring immediately following PDT and 24 hours following PDT. The conditions 
described above result in similar angio-occlusion efficiency as observed clinically after 
Visudyne®-PDT in human eye vessels of approximately the same diameter as the choroidal 
neovessels (approximated ≤ 70 μm) (142). Optimal PDT-induced vascular closure is defined as 
the closing of vessel of 70 μm or smaller in diameter, while larger vessels are left open (142). 
Fluorescent angiograms are taken of the treated area before, directly following and 48 hours 
following PDT treatment. Angiograms taken 48 hours following PDT are processed using the 
image-processing software previously described.  
Combination Visudyne®-PDT and anti-angiogenic drug therapy 
Visudyne®-PDT is performed as described above and combined with topical or intravenous 
application of Avastin® or Sutent® at different concentrations. The appropriate drug is 
administered immediately following PDT and 24 hours following PDT in a quantity of 20 μl. 
Angiographies are then taken 48 hours following the original treatment in order to visualize the 
effects of therapy. 
Image-processing quantification method 
Image-processing quantification is performed on images obtain from the florescence 
angiographies using a macro written for ImageJ (version 1.40 a; National Institute of Health; 
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Bethesda; USA) and existing plug-ins. The image-processing programs are described in more 
detail in the section of the introduction entitled: image-processing quantification programs.  
In order to perform image quantification, the image must fulfill the following criteria: a resolution 
recorded at 1280 x 1024, dynamic range of 12 bits and 4095 grey levels, magnification with x10 
(for quantification of vascular inhibition) or x4 (for quantification of vascular regrowth following 
PDT) objectives, and high contrast obtained by i.v. injection of a fluorescent contrast agent 
(FITC-dextran) and 20 μl of India ink as previously described. 
The macro returns values for parameters to indicate vascular inhibition. The parameters 
reported for in this study were selected based on their ability to best describe the phenomena 
seen in the fluorescence angiograms. The outputs of this image-processing macro include a 
skeletonized version of the vascular network, a „potential oxygenation map‟ and parameters 
describing the degree of angiogenesis inhibition. A typical example of these outputs can be 
seen in Figure 23. Figure 23A shows the original fluorescence angiogram of the CAM 
vasculature. Figure 23B shows the skeletonization network produced by the ImageJ macro and 
Figure 23C shows the „potential hypoxia map‟ where black areas represent potential hypoxic 
areas. 
 
The parameters reported to describe the degree of inhibition of the naturally developing CAM 
include: the number of branching points per mm2, defined as all equivalent and non-equivalent 
bifurcations (i.e.   3 neighbors), and the mean mesh size (or mean avascular zone) per 102 
μm2. 
 
Figure 23 An overview of the results from the image-processing program quantifying the degree of inhibition to the 
developmental CAM. A. The original fluorescent angiogram. B. The skeletonized version of the vasculature showing 
the connection between all vessels and capillaries, and capillaries and capillaries as single pixel connecting lines. C. 
The “potential oxygenation map” where possible hypoxic areas are shown in black.  
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The image-processing program which analyzes vascular regrowth following PDT is slightly 
different than the one analyzing inhibition of angiogenesis, but again produces the outputs of a 
skeletonized version of the vasculature, a „potential oxygenation map‟ and parameters 
describing the vascular density and degree of regrowth. In analyzing the regrowth of vessels 
into the PDT treated area of the CAM, four concentric circles are placed on the treated area, the 
outer most circle marking the entire treated area or the region of interest (this circle is drawn 
based on user input). The four concentric circles create four zones of revascularization, each of 
which is analyzed separately by the software. The outer most region, area 4, is the first region to 
be revascularized while the inner most region, area 1, is the last to be revascularized. A typical 
example of these outputs can be seen in Figure 24, with the original image shown in Figure 
24A, the skeletonized version of the image shown in Figure 24B and the „potential hypoxia map‟ 
shown in Figure 24C.  
 
The descriptors provided in this report to indicate vascular regrowth following PDT include: the 
branching points (per mm2); a relative measure of mean mesh size as represented by the mean 
distance between vessels in μm; and the vessel density measured as the percentage of black 
pixels in the skeletonized image scaled to the surface area analyzed. All of the graphs provided 
in the results section indicate the average value of these parameters in area 1 (the inner most 
 
Figure 24 An overview of the results of the image-processing program analyzing vascular regrowth following PDT, with 
rings marking the areas of regrowth following PDT and the outermost rings marking the entire treated area. A. The original 
fluorescent angiogram. B. The skeletonized version of the vasculature showing the connection between all vessels and 
capillaries and capillaries and capillaries as single pixel connecting lines. C. The “potential oxygenation map” where 
possible hypoxic areas are shown in black. The white bar in the lower left corner represents 200 μm and is valid for all 
images.  
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region) of vascular regrowth for low and high concentrations of each drugs. Data from the inner 
most region was selected, because this region showed the most significant difference between 
conditions due to the fact that it is the last region to be revascularized. Graphs also indicate if 
results are statistically significant in regards to the control condition based on the results of a 
student t-test. Graphs are labeled as follows: data sets with a p-value > 0.1 have no indication; 
data sets with a p-value between 0.05 and 0.1 are marked by one asterisks above the bar („*‟), 
and data sets with a p-value < 0.05 are marked by two asterisks above the bar („**‟).   
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Results 
Inhibition of developmental angiogenesis in the CAM 
 In the first experimental model, the inhibition of the physiologically-developing CAM membrane 
is investigated with the two anti-angiogenic agents: Avastin® and Sutent®. These drugs are 
topically applied to the immature membrane (embryo development days (EDD) 7 and 8) in 
concentrations ranging from 0.2 to 80 μM for Avastin® (corresponding to 0.06 to 238 
μg/embryo/day) and 2 to 1000 μM for Sutent® (corresponding to 0.02 to 10.6 μg/embryo/day). 
Physiological water (0.9% NaCl) is used as a control condition.  
Treatment of the CAM with anti-angiogenic compounds during the phase of development 
characterized by exponential vascular growth inhibits the natural development of capillaries and 
vessels and indicates the anti-angiogenic properties of the agents applied. The effects of these 
drugs are visualized by means of the fluorescence angiograms, which can be seen in Figure 25. 
Application of low drug concentrations (up to 10 and 100 μM for Avastin® and Sutent®, 
respectively) results in small avascular zones and inhibition of capillary development. The size 
of avascular zones increases with drug concentration, until capillary beds are completely 
inhibited, being replaced by networks of small blood vessels (as can be seen in the vascular 
treated with 40 μM Avastin®). Finally, at high concentrations (for 80 μM Avastin® and 700 to 
1000 μM Sutent®), nearly all capillaries and blood vessels are inhibited, leaving only large blood 
vessels. In these images, it can also be seen that both drugs act similarly at low to medium 
concentration, but that at higher concentrations, Avastin® reaches a saturation point where 
increasing drug concentration does not result in increased vascular inhibition. Sutent®, on the 
 
Figure 25 Fluorescent angiogram images of the developmental CAM treated with Avastin® (top row) and Sutent® (bottom row) at the 
concentrations indicated. These images are obtain on EDD9, following two days of topical drug application. Fluorescent angiograms 
are obtained using FITC-dextran (25 mg/kg, 20kDa, λex= 470 nm). The white bar in the upper right corner represents 200 μm and is 
valid for all images.  
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other hand, does not saturate in this manner for the molarities tested and the concentration can 
be increased until almost all blood vessels growth is inhibited (occurring at approximately 
1000μM). It should be noted that the images shown here are selected based on providing the 
most representative examples of the phenomena observed; however, results did vary between 
eggs and even within the treated area of the same egg.  
In order to obtain a more quantitative analysis of angiogenesis inhibition, images obtained from 
angiograms are processed using the image-processing program previously described (140). 
The graph of branching points as a function of drug concentration, presented in Figure 26, 
shows Sutent® and Avastin® in red. This graph shows a dose-dependent decrease in the 
number of branching points (per mm2) for both drugs. Similar to what can be seen in the 
morphological images shown above, a decreasing number of branching points indicates an 
increasing level of inhibition as the vascular network becomes less complex and the number of 
capillaries is decreased. At the lowest concentration of Avastin® (0.2 μM) a small degree of 
stimulation can be seen, as the number of branching points slightly increases. Following this 
increase, the number of branching points decreases to a greater degree than the number of 
branching points for Sutent® at similar concentrations. Therefore, it appears that Avastin® is a 
more effective inhibitor of angiogenesis at low concentrations. Overall, however, the trends of 
inhibition for both drugs at low concentrations appear to be relatively similar. At high 
 
Figure 26 Number of branching points (per mm
2
) as a function of drug concentration. Error bars represent the 
Standard Error of the Mean (SEM) of measurements.  
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concentrations, Sutent® continues to inhibit angiogenesis until nearly all vasculature is 
destroyed. The efficiency of Sutent® at high concentrations is much greater (approximately two 
times higher) than Avastin® at its most effective concentration.  
The graph of mean mesh size as a function of drug concentration is presented in Figure 27. 
This graph again shows a dose-dependent increase in the mean mesh size as drug 
concentration is increased. A log scale was selected for both axes in order to better show the 
effects of each drug at low concentrations. Increased inhibition is reflected by an increase in the 
mean mesh size, as the inhibition of blood vessel and capillaries growth results in an increase in 
the area of avascular zones. In addition, the trends of the mean mesh size and the number of 
branching points are similar, as these parameters are fundamentally related to each other. 
These results again show a small amount of stimulation of angiogenesis for Avastin® at very low 
concentrations. This is followed by a mean mesh size which increases as drug concentration is 
increased. Based on this parameter, Avastin® is still seen to be a more effective inhibitor of 
angiogenesis than Sutent® at low concentrations, while greater Sutent® efficiency is seen at 
higher concentrations. In addition, the mean mesh parameter better shows the saturation of 
Avastin® seen in the fluorescence angiograms between the concentrations 40 and 80 μM. 
Between these concentrations, the mean mesh size of the vascular treated actually slightly 
decreases, within the margin of error, showing no significant increase in the ability of the drug to 
 
Figure 27 Mean mesh size (per 10
2
 μm
2
) as a function of drug concentration. Error bars represent the SEM.  
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inhibit angiogenesis with increased concentration. Sutent®, on the other hand, shows no 
saturation as the mean mesh size continues to increase with drug concentration.  
Both drugs showed effective inhibition of angiogenesis in the physiologically-developing CAM. 
The effective dose to achieve 50% inhibition (ED50) for each drug was determined based on the 
percent of inhibition in comparison to the control condition averaged for the two parameters 
provided above. ED50 was seen at 45 and 200 μM for Avastin
® and Sutent®, respectively, 
corresponding to doses of 134 and 2.1 μg/embryo/day.  
Inhibition of PDT-induced angiogenesis in the CAM 
In the second experimental model, the effects of anti-angiogenic drugs on the regrowth of blood 
vessels following photodynamic damage to the CAM vasculature are examined. Visudyne®-PDT 
applied to the mature CAM on EDD11 results in the effective closure of small blood vessels 
(diameter of 100 μm or less) followed by the induction of angiogenesis. Regrowth of vasculature 
can be seen following PDT and complete revascularization is seen for control conditions (PDT 
with physiological water) 48 hours following PDT (143). Figure 28 shows a typical example of 
vascular regrowth in control conditions following PDT: the CAM vasculature before PDT 
treatment (Figure 28A), the same area of the CAM directly following PDT (B), the start of 
vascular regrowth at 24 hours following PDT (C) and complete revascularization at 48 hours 
following PDT (D). This figure not only serves to show the complete revascularization of the 
treated area 48 hours following treatment, but also shows the changed morphology of new 
vasculature compared to untreated vasculature (which can be seen outside of the treated area).  
 
Figure 28 The CAM vasculature before PDT (A), directly following PDT (B), 24 hours following PDT (C) and 48 hours following PDT 
(D). Under control conditions (shown here) vascular regrowth is complete 48 hours after treatment. Visualization of vasculature is 
achieved through fluorescence angiograms using FITC-dextran (25 mg/kg, 20kDa, λex= 470 nm). The white bar in the lower left 
corner represents 200 μm and is valid for all images. 
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The morphological difference between new vessels and untreated vessels can be seen in the 
increased tortuosity or unorganized, chaotic nature of the regrown vessels. An image showing 
vascular abnormalities can be found in Figure 29. In addition to showing increased tortuosity, 
this vasculature is characterized by increased mesh size (larger avascular zones) and 
occasionally increased thickness of regrown blood vessels (indicated by the arrows). These 
changes in vasculature most likely reflect the induction of angiogenesis in the treated area due 
to vascular damage from PDT through the activation of different pathways than those normally 
activated in the physiological development of the CAM.  
 
 
 
 
 
 
 
 
 
 
Topically administrated angiogenesis-inhibitors 
In order to test the effects of anti-angiogenic drugs on PDT-induced angiogenesis, Visudyne®-
PDT is performed on the mature CAM vasculature on EDD11 and drugs are topically applied 
directly following and 24 hours following therapy. Vascular regrowth is then visualized 48 hours 
following the original therapy using fluorescence angiograms. For each drug, concentrations of 
2 or 20 μM are tested, corresponding to 6 or 60 μg/embryo/day for Avastin® and 0.02 or 0.2 
μg/embryo/day for Sutent®. The morphological effects of these drugs on vascular regrowth 48 
hours following vascular occlusion due to PDT can be seen in Figure 30. These images show 
 
Figure 29 Image showing abnormalities in the 
revascularized PDT treated area. The treated area is 
indicated by the yellow circle. Regrown blood vessels 
appear tortuous with abnormally large avascular zones 
and increased vessel diameters (indicated by the 
arrows). The white bar in the lower right corner 
represents 200 μm. 
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the varying abilities of these anti-angiogenic agents to prevent vascular regrowth. It can be seen 
that even low drug concentrations (much lower than concentrations needed to inhibit 
physiological angiogenesis) are capable of inhibiting the angiogenic state induced by 
photodynamic vascular damage when compared to the control condition. There appears to be 
dose-dependent inhibition for both drugs, as the percent of the treated area to be revascularized 
appears to decrease with increasing concentration. It can be seen that Avastin® appears to 
results in stronger inhibition of angiogenesis than Sutent® at low and high concentration. The 
different effects of each drug on angiogenesis, however, are more pronounced at 20 μM than at 
2 μM. In Figure 30, it can be seen that using Sutent® as an anti-angiogenic agent results in less 
inhibition, as well as more organized and physiologically normal appearing regrown blood 
vessels. On the other hand, when Avastin® is applied at 20 μM, it results in the growth of blood 
vessels which are much more chaotic and are characterized by much larger avascular zones, 
as can be seen in Figure 30.  
 
 
Figure 30 Examples of fluorescence angiograms obtain 48 hours follow Visudyne®-PDT (0.2 mg/kg embryo weight, λex = 420 
nm, λem > 470 nm; light dose of 20 J/cm
2
, irradiance 50 mW/cm
2
, drug-light interval 1 minute). The control condition is 
shown on the left, Sutent® low and high concentrations are shown on the top row and Avastin® low and high 
concentrations are shown on the bottom row. The original treatment area is outlined by the yellow circles. The vasculature 
is visualized using FITC-dextran fluorescence angiography (25 mg/kg, 20 kDa, λex = 470 nm, λem > 520 nm). The white bar in 
the upper right corner represents 200 μm and is valid for all images.  
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Again, more quantitative information can be obtained through image-processing of fluorescence 
angiogram obtained on EDD13, 48 hours following PDT treatment.  
The graph of branching points in region 1 of vascular regrowth, presented in Figure 31, shows 
the control condition of PDT monotherapy in the first column (red), PDT in combination with low 
drug concentration, 2 μM, in the second set of columns, with Avastin® in blue and Sutent® in 
yellow, and PDT in combination with high drug concentration, 20 μM, Avastin® and Sutent® in 
the third set of columns. This graph shows that both drugs are capable of inhibiting vascular 
regrowth following PDT when compared to the control condition. In addition, both drugs show 
similar inhibition at low concentrations, while Avastin® appears slightly more effective at high 
concentrations (but not significantly, p-value 0.23). Based on this parameter, Avastin® shows 
dose-dependent inhibition as the difference between low and high concentration is significant 
given a confidence interval of 10% (p-value of 0.085). Sutent®, on the other hand, does not 
show dose-dependent inhibition as the difference between low and high concentration is not 
significant (p-value 0.5).  
 
The graph of relative mean mesh size in region 1 of vascular regrowth is presented in Figure 32. 
As the parameter for the mean distance to the next vessel increases, the area of the mean 
 
Figure 31 Graph of branching points per mm
2
 in region 1 of vascular regrowth following PDT. Control, low and 
high concentrations are shown for both Avastin® and Sutent®. Error bars show SEM. Data sets marked by ‘**’ 
have a p-value < 0.05.  
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mesh size also increases, indicating a greater degree of inhibition. Based on this parameter, 
both drugs show the ability to inhibit vascular regrowth in the central region of the PDT-treated 
area in comparison to the control condition. Both drugs appear to show dose dependent 
inhibition, as inhibition increases between low and high concentration, however neither 
difference is statistically significant (p-value 0.23 and 0.37 for Avastin® and Sutent®, 
respectively). In addition, Avastin® again appears to be a better inhibitor of vascular regrowth 
than Sutent®; however, at both high and low concentrations, the difference between the 
performances of the two drugs is not statistically significant (p-value 0.55 and 0.23 for high and 
low concentration, respectively).  
 
The graph of percent vessel density in region 1 of the PDT-treated area is shown in Figure 33. 
The vessel density represent the percentage of the region being analyzed covered in regrown 
blood vessels. Smaller vessel density values indicate a greater degree of inhibition of 
angiogenesis, as it indicates that a smaller percentage of the treated area has been 
revascularized. Based on the parameter of percent vessel density, both drugs show the ability to 
inhibit angiogenesis in comparison to the control condition. Again this parameter shows 
Avastin® to be a slightly more effective inhibitor of angiogenesis at both concentrations, but 
again neither of these differences are statistically significant (p-value 0.64 and 0.23 for low and 
 
Figure 32 Graph of the relative vascular mesh size in region 1 of vascular regrowth following PDT. Control, low and 
high concentrations are shown for both Avastin® and Sutent®. Error bars show SEM. Data sets marked by ‘*’ have a 
p-value between 0.05 and 0.1, and data sets marked by ‘**’ have a p-value < 0.05. 
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high concentration, respectively). Inhibition also appears to be dose dependent for both drugs, 
but the differences between low and high concentration for each drug are also not significant.  
 
Both drugs showed effective inhibition of the angiogenic state induced by photodynamic 
damage in comparison to the control. The differences between Avastin® and Sutent® at high or 
low concentrations are not statistically significant based on any of the parameters analyzed. In 
addition, the difference between Sutent® low and high concentration is not statistically 
significant, while the difference for Avastin® between low and high concentration is statistically 
significant given a 10% confidence interval, but only for the branching points parameter (p-value 
of 0.085).  
The estimated effective doses of 50% inhibition (ED50) for each drug is determined based on the 
percent of inhibition in comparison to the control condition averages for the parameters 
presented above. The estimated ED50 for inhibition of the PDT-induced angiogenic state was 
seen at 7 and 17 μM for Avastin® and Sutent®, respectively, corresponding to a treatment dose 
of 20.9 and 0.18 μg/embryo/day. These concentrations had to be estimated due to the fact that 
50% inhibition was not attained for the parameter of vessel density for Sutent® and had to be 
calculated assuming a linear trend.  
 
Figure 33 Graph of percent vessel density in region 1 of vascular regrowth following PDT. Control, low and high 
concentrations are shown for both Avastin® and Sutent®. Error bars show SEM. Data sets marked by ‘**’ have a 
p-value < 0.05.  
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Intravenously administrated angiogenesis-inhibitors 
Subsequently, the effects of intravenously applied Sutent® following PDT were investigated in 
order to determine the relationship between intravenous and topical drug uptake and delivery. 
These experiments were performed for both drugs; however, due to time limitations, only 
adequate results were obtained for Sutent®. Images depicting the morphological effects of 
Sutent® therapy are provided in Figure 34.  In this figure, the effects of topical drug application 
can be seen in images in the top row (low and high concentration) and effects of intravenous 
drug application can be seen in images on the bottom row (low and high concentration). These 
images show more effective inhibition of PDT-induced angiogenesis by Sutent® when it is 
topically administered compared to when it is intravenously administration. Intravenously 
administered Sutent® at low concentration appears to have little to no effect on angiogenesis, as 
the treated area is completely revascularized 48 hours after treatment.  At high concentration, 
intravenously administered Sutent® does appear to inhibit revascularization of the treated area, 
but not very strongly as the area is partially regrown and looks very similar to the 2 μM topical 
 
Figure 34 Examples of fluorescence angiograms obtain 48 hours follow Visudyne®-PDT (0.2 mg/kg embryo weight, λex = 
420 nm, λem > 470 nm; light dose of 20 J/cm
2
, irradiance 50 mW/cm
2
, drug-light interval 1 minute). The control condition 
is shown on the left, Sutent® low and high concentration topically applied are shown in the top row, and Sutent® low and 
high concentration are shown in the bottom row. The original treatment area is outlined by the yellow circles. The 
vasculature is visualized using FITC-dextran fluorescence angiography (25 mg/kg, 20 kDa, λex = 470 nm, λem > 520 nm). The 
white bar in the upper right corner represents 200 μm and is valid for all images.  
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Sutent® treatment condition shown in the top row.  In addition, these images show that the 
morphology of regrown blood vessels in the presence of topical and intravenously administered 
Sutent® are relatively similar, both being less tortuous and disorganized when compared to 
blood vessel that regrow in the presence of Avastin®.   
Data obtained from image-processing allowed for the generation of the graph of the percent 
vessel density provided in Figure 35. This graph presents the percent vessel density, in region 1 
of vascular regrowth, for the control PDT condition (first column, red), 2 μM, low concentration of 
Sutent® (the second set of columns, topical in yellow and intravenous in blue), and 20 μM, high 
concentration of Sutent® (the third set of columns, topical in yellow and intravenous in blue). 
Based on this graph, topically applied Sutent® is significantly more effective at inhibiting 
vascular regrowth following PDT than intravenously applied Sutent® given a confidence interval 
of 10% (p-value of approximately 0.09 for low and high concentration). In addition, neither of the 
intravenous conditions showed significant inhibition in comparison to the control. Based on the 
parameter of vessel density, the estimated ED30 for topically and intravenously applied Sutent
® 
was seen at 2 and 38 μM, corresponding to 0.02 and 0.4 μg/embryo/day, respectively. The ED30 
was calculated for this parameter, because a level of inhibition in comparison to the control high 
enough to calculate the ED50 was not achieved for intravenously administered Sutent
®.    
 
Figure 35 Graph of the percent vessel density in region 1 of vascular region for the PDT alone control (red), and 
low and high concentrations of Sutent® applied topically (yellow) and intravenously (blue). Error bars show 
SEM. Data sets marked by ‘**’ have a p-value < 0.05 and data sets with no marking have a p-value > 0.1.  
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Discussion and Conclusions 
The CAM model is extensively used in angiogenic research and is particularly well suited for the 
study of diseases characterized by proliferative retinal vasculature, such as age-related macular 
degeneration (29). 
In the present work, this model was used in order to study the effects of vascular regrowth 
following photodynamic occlusion of vessels in the presence of anti-angiogenic drugs targeting 
two different mechanisms: direct inhibition of vascular endothelial growth factor (VEGF) through 
a monoclonal antibody, such as Avastin®, or inhibition of VEGF and other pro-angiogenic 
signaling through the receptor tyrosine kinase inhibitor (RTKI) Sutent®.  
The aim of showing the efficiency of a RTKI in preventing angiogenesis and vascular regrowth 
following photodynamic vascular occlusion is to open up the possibility for a new therapeutic 
modality, which would present unique advantages over current therapeutic options. The 
advantage of using a small molecule-based drug, such as Sutent®, in the treatment of AMD in 
the place of a large molecule, such as Avastin®, is based on the bioavailibity of the drug. Being 
a small molecule which is mostly hydrophobic, Sutent® can pass through cell membranes to 
interact with the intracellular domains of receptor tyrosine kinases involved in the angiogenic 
signaling cascade. This properties of Sutent® may well make it possible for drug application to 
be achieved both locally and topically through either slow release drug delivery systems or eye 
drops (56). This presents a potential advantage over Avastin®, which is currently administered 
through intravitreal injection. Multiple treatments of anti-angiogenic drugs are required and, as 
one can imagine, the advantages of a less invasive mode of drug administration would be great. 
In addition to this practical advantage, a locally-administered RTKI drug would likely bypass 
many of the common complications associated with anti-angiogenic drug therapy. First of all, 
local drug administration will probably decrease the development of systemic side effects and 
hopefully result in only the desired therapeutic effects of the drug. More importantly, drug 
resistance is less likely to develop when using a RTKI for the treatment of AMD, as the believed 
mechanisms by which resistance can develop are based on the abilities of cancerous cells to 
mutate and circumvent some of the pathways inhibited by the anti-angiogenic drug therapy. It is 
believed that because the vasculature being treated here is genetically stable, these 
mechanisms of resistance will not be available, and drug resistance will not develop.  
It is also possible that by targeting a new pathway additional benefits or increased efficiencies 
may be seen which was not predicted. Targeting RTKIs opens up the possibility for new 
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combination therapies which have not previously been available. The use of multiple RTKIs or 
the combination of a RTKI with a VEGF-targeting molecule could provide additional benefits and 
synergistic effects not foreseen. In addition to additional therapeutic benefits from combination 
therapies, however, there is also the risk that combining anti-angiogenic drugs could result in 
unforeseen side effects and complications. Local administration of anti-angiogenic drugs can 
also improve the effectiveness of PDT, as drug application prior to PDT results in vascular 
normalization, increasing the availability of both PSs and oxygen in the blood vessels during 
treatment, improving the efficiency of PDT (142).  
The results of this research showed that both of the drugs tested were able to inhibit physiologic 
and PDT-induced angiogenesis. In both situations, Avastin® appeared to be a slightly more 
effective inhibitor of angiogenesis than Sutent®, but statistical analysis of the data revealed that 
these differences were not significant. In the physiological angiogenic state, Avastin® appeared 
to reach a saturation point which was not seen for Sutent®. This saturation was most likely due 
to the fact that Avastin® is a large molecule which has a limited ability to penetrate blood vessels 
to bind and neutralize VEGF, while Sutent® concentration can be increased until it completely 
floods cells blocking nearly all of its target RTK pathways. The therapeutic relevance of this 
result, however, is not very significant due to the fact that concentrations higher than this 
saturation point (or concentrations of Sutent® needed to completely inhibit blood vessel growth) 
are much greater than any concentration which would be used in a clinical setting.  
It should be noted that it is difficult to make direct comparisons between the two drugs being 
examined in this study. This is due to the fact that the drugs have drastically different molecular 
weights (Avastin® is three orders of magnitude larger than Sutent®), have different properties 
and bioavailabilities, and the fact that they target different.  In this study, the drug molarity is 
predominantly used to indicate doses applied the CAM; however this can be misleading as a 
relatively high molarity of Sutent® still represents a relatively small dose in terms of μg of drug 
administered embryo when compared to the dose given in μg of even very low molarities of 
Avastin®. For this reason, all effective doses are provided in molarity and in terms of μg per 
embryo.  
The ED50 for Avastin
® and Sutent® to inhibit the developmental angiogenic CAM was seen when 
20 μl of 45 or 200 μM drug were applied to the CAM topically each day for two days, 
respectively, which corresponds to 134 and 2.1 μg/embryo/day. In clinical treatment of cancer, 
Avastin® is applied in an intravenous dose of 1 to 10 mg/kg which corresponds to 20 μl of 3.4 to 
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33.6 μM applied to the CAM. Sutent® is administered orally in a dose of 12.5, 25 or 50 mg per 
day. Taking the middle dose (25mg) and assuming an average mass of 70 kg for a person, this 
dose corresponds to 0.357 mg/kg which corresponds to 20 μl of 335 μM Sutent® applied to the 
CAM. Therefore, the ED50 of Avastin
® needed to inhibit the naturally-developing CAM 
vasculature is slightly higher than what is clinically used (45 instead of 33.6 μM) and the Sutent® 
needed is lower than the clinical doses (200 instead of 335 μM).  
The estimated ED50 for Avastin
® and Sutent® to inhibit the PDT-induced angiogenic state on the 
CAM was seen when 20 μl of 7 or 17 μM drug were applied to the CAM topically each day for 
two days, respectively, corresponding to 20.9 and 0.18 μg/embryo/day. The effective dose of 
Avastin® fell within the clinically-used range of doses while the effective dose of Sutent® was 
approximately 20 times lower than the clinically-used dose for cancer therapy.  
In addition to determining the effective concentration of each drug to inhibit the physiologic and 
PDT-induced angiogenic states, this research allows for a fundamental comparison of these two 
angiogenic states to be made. A notable result is the fact that inhibition of the PDT-induced 
angiogenic state was achieved at a much lower concentrations than inhibition of the 
physiologically angiogenic CAM. Inhibition of the PDT-induced angiogenic state occurred at a 
concentration approximately 2-3 fold lower than the developmental CAM for Avastin® and 4-fold 
for Sutent®. This result could reflect fundamental differences between the angiogenic states and 
the pathways they activate in order to achieve their desired biological responses. It may be the 
case that PDT-induced angiogenesis only activates specific pathways associated with the 
vascular damage done by PDT. For example, PDT induces hypoxia through vascular occlusion, 
resulting in the activation of HIF and the release of VEGF. One could speculate that while 
physiologic angiogenesis is a result of the activation of many closely regulated angiogenic 
pathways (such as VEGF, angiopoietins, EGF, PDGF or PIGF (143)), PDT-induced 
angiogenesis may be mainly a result of one or a few pathways activated due to hypoxia, 
inflammation and cell damage (143). Morphological characteristics of the vasculature which 
regrows after PDT damage also appear to support the hypothesis that this form of angiogenesis 
may be mainly VEGF-driven. This vasculature is abnormally tortuous and disorganized, having 
characteristics similar to tumor vasculature, which is known to be mainly VEGF-driven (142).  
The estimated ED30 for topically and intravenous applied Sutent
® was seen when 20 μl of 2 and 
38 μM drug were applied each day for two days, respectively, corresponding to 0.02 and 0.4 
μg/embryo/day, respectively. Again doses are much lower than what is clinically used for cancer 
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treatment and would remain lower even if it were possible to calculate the ED50 for this 
parameter.  
The method of direct topical drug application was selected because it most closely reflects 
topical drug application via droplet to the eye, or application through a slow release drug 
delivery system, which are the primary models being investigated by this research. Intravenous 
drug application, however, was also performed for low and high concentrations of Sutent® in 
order to obtain more information about the activity of the drug and determine the relationship 
between these modes of drug administration. The results of these experiments showed that 
topical Sutent® application results in stronger inhibitions than intravenous application. This result 
can be explained by the fact that Sutent® is a small molecule drug, which when applied locally 
and topically has no problems entering cells to have its desired effect. By administering Sutent® 
systemically through intravenous injection, the drug concentration is effectively diluted by the 
volume of blood in the system and the concentration of drug reaching the desired area is 
reduced. This characteristic of Sutent® may also explain why effective angiogenesis-inhibiting 
doses could be achieved at lower concentrations than those used in the clinical treatment of 
cancer, which is also achieved through systemic administration. This result strongly supports 
the hypothesis that local application of Sutent® in the form of eye drops or slow-release drug 
delivery systems could provide an effective form of treatment for the choroidal neovessels which 
develop in age-related macular degeneration.  
The preliminary results obtained with Avastin® show stronger inhibition of angiogenesis when 
this drug is administered intravenously as compared to topical application (data unshown). This 
result could be explained by the fact that Avastin® is a large molecule, which can enter in direct 
contact with VEGF when injected into the blood, allowing it to have a stronger effect than when 
it must pass into blood vessels due to being topically applied. 
In addition, a recent study conducted in this laboratory (The Medical Photonics Group) was 
done to compare the effects of three different RTKIs, including Sutent®, with Avastin® in 
inhibiting developmental angiogenesis and vascular regrowth following PDT-induced vascular 
occlusion. This study showed Sutent® to have similar effectiveness as one of the RTKIs 
(erlotinib) and to be less effective than the other RTKI (sorafenib). In addition, morphological 
characteristics of regrown vasculature varied not only between Avastin® and the RTKIs, but 
between the different RTKIs as well. This indicates that different pathways are being inhibited by 
the different RTKIs, and that inhibition of different pathways results in angiogenesis achieved 
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through different mechanisms which is reflected in the structure and morphology of regrown 
vessels (143). These results further support the potential of using RTKIs in the treatment of 
angiogenic disorders.    
Finally, it should be noted that it is complicated to translate the concentrations or doses applied 
to the CAM into doses administered in clinical applications. This is due to the following 
difficulties. The method of drug administration in clinical applications varies with the methods 
used in the research protocol (oral administration for Sutent® and intravenous administration for 
Avastin®), which results in different absorption and bioavailability of the drugs. There is 
effectively an overall lack of information concerning serum and blood concentrations of drugs, 
and there are important difficulties in translating results between a chicken and human. The two 
drugs examined are targeted to human VEGF and human RTKs. It can be seen that these 
drugs have an affinity for the chicken counterpart of their target molecule (by the fact that they 
have anti-angiogenic effects), but it is impossible to determine how a decrease in affinity can 
change the effectiveness of these drugs. This model and this research, therefore, are not being 
used to determine exact effective concentrations or to make a direct translation to clinical 
application, but instead serve to determine general trends and interactions of molecules and 
drugs in order to determine if these therapies are viable treatment options which should be 
investigated in more depth.  
Experiments testing the effectiveness of the inhibition of physiologic and PDT-induced 
angiogenic states on the CAM showed that both the drugs tested were capable of inhibiting 
angiogenesis in comparison to the control condition and, more importantly, that there was no 
statistically significant difference between the activity of the two drugs. The results of this 
research support the theory that a small-molecule receptor tyrosine kinase inhibitor, such as 
Sutent®, is capable of inhibiting PDT-induced angiogenesis and that molecules such as this one 
could provide effective anti-angiogenic properties in the treatment of angiogenic disorders such 
as age-related macular degeneration and cancer. In addition, topically applied Sutent® was 
seen to be a more effective inhibitor of the PDT-induced angiogenesis than intravenously 
administered Sutent®, supporting the theory that a locally-applied receptor tyrosine kinase 
inhibitor could be used in the treatment of age-related macular degeneration. 
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Abbreviations 
 
AMD Age-related macular degeneration 
Ang Angiopoietin 
BCC Basal cell carcinoma 
BM Basement membrane 
BPD-MA Benzoporphyrin derivative monoacid  
CAM Chorioallantoic membrane 
CATT Comparison of AMD treatment trials 
CNV Choroidal neovessel 
Da Daltons  
ECM Extracellular matrix 
ED50 Effective dose of 50% 
EDD Embryo development day 
EGF  Epidermal growth factor 
FFT Fast Fourier transform 
FGF Fibroblast growth factor 
FGFR Fibroblast growth factor receptor 
GIST Gastrointestinal stromal tumor 
HIF Hypoxia inducible factor 
IC Internal conversion 
ISC Intersystem crossing 
LDL Low density lipoprotein 
OCT Optical coherence topographies 
PDGF Platelet-derived growth factor 
PDGFR Platelet-derived growth factor receptor 
PDT Photodynamic therapy 
Pgp P-glycoprotein 
PNET Pancreatic neuroendocrine tumor 
PS Photosensitizer 
PS* Excited state 
PTPC Permeability transition pore complex 
RCC Renal cell carcinoma 
RPE Retinal pigment epithelium 
RTK Receptor tyrosine kinase 
RTKI Receptor tyrosine kinase inhibitor 
S0 Ground state 
S1 Singlet state 
SD Standard deviation 
SEM Standard error of mean 
T1 Triplet state 
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TGF Tumor growth factor 
VEGF Vascular endothelial growth factor 
VEGFR Vascular endothelial growth factor receptor 
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